Holla personal page - To The Moon

Holla

Holla

No personal profile

598Follow

60Followers

0Topic

0Badge

2021-09-18

Like pls

FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations

2021-07-28

Like my comment pls

Sorry, the original content has been removed

2021-09-18

Like pls

Lucid Motors Price Predictions: Can LCID Stock Really Reach $30?

2021-09-14

Like pls

These 2 High-Growth Stocks Could Help Power the Bull Market's Next Record Run

2021-09-10

Like pls

3 Effective Strategies for Finding Value in Any Market

2021-07-24

Like my comment pls

Tesla Earnings Are Coming. Here’s the One Number That Matters.

2021-03-31

Like if u long any of them!

Sorry, the original content has been removed

2021-07-23

Like my comment pls

Wall Street ekes out gains, led by tech, growth stocks

2021-07-08

Like my comment pls

Wells Fargo Tells Customers It's Shuttering All Personal Lines Of Credit

2021-06-11

Like my comment pls

Tesla Begins Deliveries Of Model S Plaid: Everything You Need To Know

2021-06-01

Like my comment pls

Here Are the 11 Best Performing IPOs of the Year

2021-04-18

Like my comment pls

Fed’s Waller says the economy is ‘ready to rip’ but policy should stay put

2021-07-20

Like my comment pls

Coronavirus Stocks Are Zooming Higher Today

2021-04-30

Reply my comment pls

Tesla Stock Has Many Risks. EV Credits Isn’t One of Them.

2021-09-18

Like pls

HLBZ Stock: What to Know as Little-Known Helbiz Rockets Higher

2021-09-13

Like pls

Sorry, the original content has been removed

2021-09-05

Like pls

Beat the market with this quant system that’s very bullish on stocks at record highs

2021-08-16

Like pls

Wish, Palantir, AMC, Clover Heealth, GameStop And More — Stocks On WallStreetBets Radar Heading Into New Week

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3565687171198207,"uuid":"3565687171198207","gmtCreate":1603456554890,"gmtModify":1603462800212,"name":"Holla","pinyin":"holla","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":60,"headSize":598,"tweetSize":715,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.42%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.10%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":863684015,"gmtCreate":1632386212737,"gmtModify":1676530769608,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>&amp;$$","listText":"<a href=\"https://laohu8.com/S/DIDI\">$DiDi Global Inc.(DIDI)$</a>&amp;$$","text":"$DiDi Global Inc.(DIDI)$&$$","images":[{"img":"https://static.tigerbbs.com/054293ac42dfdd86872cccbf8b383b96","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863684015","isVote":1,"tweetType":1,"viewCount":230,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":869675017,"gmtCreate":1632286641939,"gmtModify":1676530743596,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SKLZ\">$Skillz Inc(SKLZ)$</a>$$$$","listText":"<a href=\"https://laohu8.com/S/SKLZ\">$Skillz Inc(SKLZ)$</a>$$$$","text":"$Skillz Inc(SKLZ)$$$$$","images":[{"img":"https://static.tigerbbs.com/7a62dc01bb9a6c4c1f59565c7a0dd074","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869675017","isVote":1,"tweetType":1,"viewCount":48,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":860717576,"gmtCreate":1632212556895,"gmtModify":1676530726210,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/860717576","repostId":"1116085013","repostType":4,"repost":{"id":"1116085013","pubTimestamp":1632210464,"share":"https://www.laohu8.com/m/news/1116085013?lang=&edition=full","pubTime":"2021-09-21 15:47","market":"us","language":"en","title":"\"Ice Is Coming\": Morgan Stanley Warns Odds Of \"Destructive\" 20%+ Correction Are Rising","url":"https://stock-news.laohu8.com/highlight/detail?id=1116085013","media":"zerohedge","summary":"One month ago,we saidthat when Morgan Stanley's chief equity strategist Michael Wilson hiked his yea","content":"<p>One month ago,we saidthat when Morgan Stanley's chief equity strategist Michael Wilson hiked his year-end price target from 3,900 to 4,000,he did so very \"reluctantly\", as if someone was tapping on his shoulder with an Uzi, because while the note was supposed to be cheerful and rosy, all Wilson could talk about was the downside scenario which included all the usual sorts of fire and brimstone.</p>\n<p>Well, fast forward to today when suddenly global markets are writing under the throes of Evergrande contagion sending spoos sharply below their 50DMA critical support level, and when early this morning, Michael Wilson is back in his prime as Wall Street's biggest bear, going back to his core thesis that the current Mid-cycle transition will end in either \"Fire\", i.e. a sharp market correction...</p>\n<p><img src=\"https://static.tigerbbs.com/f03ee796bfffefa1bc3cffeeef90f8b9\" tg-width=\"500\" tg-height=\"294\" width=\"100%\" height=\"auto\"></p>\n<p>... or \"Ice\", with consumer spending grinding to a halt...</p>\n<p><img src=\"https://static.tigerbbs.com/fb15b3b94d76ad3296dda6ebefe0e59d\" tg-width=\"500\" tg-height=\"292\" width=\"100%\" height=\"auto\">... and observes that \"the ice scenario would be worse for markets and we are leaning in that direction given the fall in consumer confidence and reset lower in PMIs we expect.\"</p>\n<p>Backing up a bit, for those unaware, since March, Wilson had been espoused a mid-cycle transition narrative for US Equity markets, which he says has played out to script for the most part, with large-cap quality outperforming while the average stock has materially underperformed the S&amp;P 500, the exact opposite of what occurred during the early cycle phase of recovery.</p>\n<p><img src=\"https://static.tigerbbs.com/72ee33a6f5ec5ad4dc413fea6b6702e6\" tg-width=\"1014\" tg-height=\"319\" width=\"100%\" height=\"auto\">Relieved that he no longer has to hide his bearish views behind a facade of cheerful optimism (observed most recently during his August S&amp;P target hike), Wilson than mocks the \"many commentators and clients\" who continue to point to the S&amp;P 500 near all-time highs as a leading indicator and rationale for even higher prices ahead, and cautions that in his view, \"the relative strength of the S&amp;P 500 and Nasdaq 100 is further confirmation that the market understands the mid-cycle transition narrative and has bought into it hook, line and sinker. After all, the S&amp;P 500 is the highest quality large cap index in the world.<b>In short, it should be outperforming right now.\"</b></p>\n<p>The question, as Wilson puts it, whether the mid-cycle transition will end with a correction in this index as it typically does, or whether it's different this time? His prediction:<b>\"With our year end target 10% below current levels, our view is clear: the mid-cycle transition will end with the rolling correction finally hitting the S&amp;P 500.\"</b></p>\n<p>And so, for the benefit incredulous bulls who can't believe all the red they are seeing this morning, Wilson explains that \"the mid-cycle transition will end with the rolling correction finally hitting the S&amp;P 500.\" He then reminds MS clients that he has laid out two near-term risk paths that could lead to this outcome: \"<i>fire\" (the Fed begins to remove monetary accommodation in response to an overheating economy) and \"ice\" (earnings revisions and higher frequency macro data points decelerate amid demand pull forward, supply chain issues and margin pressure).</i>\"</p>\n<p>And while in his weekly note he dives deeper into both of these paths and points \"to accelerating risks on both the policy and growth fronts\" the emphasis is on the \"Ice\" scenario which could result in \"<b>a mode destructive outcome, i.e., a 20%+ correction.\"</b>Here's why:</p>\n<p>The typical mid-cycle \"fire\" outcome would lead to a modest and healthy 10% correction in the S&amp;P 500.<b>However, the \"ice\" scenario is starting to look more likely, and could result in a more destructive outcome – i.e. a 20%+ correction.</b>As a result, we continue to recommend a barbell of more defensively oriented quality (Healthcare and Staples) to protect from the \"ice\" scenario while keeping a leg in Financials to participate in the \"fire\" outcome as higher rates materialize.</p>\n<p>The next question is what would catalyze the upcoming correction, whether it is the 10% \"fire\" or 20% \"ice\" drop. Wilson responds:</p>\n<blockquote>\n We have presented two potential scenarios for why / how the correction will ensue. The more traditional ending to a mid-cycle transition is a \"fire\" outcome whereby the recovery overheats and the Fed begins to remove accommodation. In the 1994 and 2004 transitions, that meant raising the Fed Funds Rate. In 2011, it was simply the ending of QE2.\n <b>This time we think it is the tapering of asset purchases later this year/early next year.</b>Given that the taper was effectively pre-announced at Jackson Hole 3 weeks ago, is it a coincidence that equity markets have been softer in September? Under this scenario, the economy reaccelerates from the summer slowdown but not enough to offset the tightening of financial conditions from higher back end rates and less liquidity in the system. In addition to the anticipated tapering of asset purchases later this year, we point to the fact that the Treasury's General Account (TGA) has fallen by $1T since March (Exhibit 3).\n</blockquote>\n<p><img src=\"https://static.tigerbbs.com/754e4d93ff6f216463eee7df5dfa1bde\" tg-width=\"1027\" tg-height=\"340\" width=\"100%\" height=\"auto\"></p>\n<p>While this has been a good offset to the decelerating M2 growth (Exhibit 4), that offset is probably finished now. Bottom line, this is the time of the mid cycle transition when P/Es for the broader index properly contract (Exhibit 5).</p>\n<p><img src=\"https://static.tigerbbs.com/d87b7fac22f1a1f5db68fec641fc7528\" tg-width=\"703\" tg-height=\"363\" width=\"100%\" height=\"auto\"></p>\n<p>Piling on the pessimism, Wilson then notes that \"there are several key variables we are monitoring that currently support a view for a worse than expected growth deceleration.\"</p>\n<ul>\n <li><b>First is NTM earnings estimates.</b>Even if the economy rebounds in 4Q from the slowdown this summer, it likely won't translate into higher earnings estimates as incremental margins rollover due to higher costs and taxes. This is the mirror image of the past year when costs were being eliminated as revenues benefitted greatly from the fiscal stimulus. Indeed, NTM EPS estimates for the S&amp;P 500 appear to have been flattening out over the past month after a record recovery to levels that are 20% above the prior peak (Exhibit 6). This will be critical to watch as we enter 3Q earnings season and companies update investors on costs/margins and potential payback in demand from the consumption binge earlier this year.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/fd04066c66b0146205ae7b7590be18f1\" tg-width=\"702\" tg-height=\"420\" width=\"100%\" height=\"auto\">Another way to analyze this rate of change on earnings momentum is to look at<b>earnings revision breadth (or ERB)</b>, which Wilson thinks is vulnerable to a simple reversion to the mean from today's very elevated levels of +2 standard deviations (Exhibit 7).<b>If earnings revision breadth (ERB) normalizes to its average over the next 3 months, the S&amp;P should fall approximately 11%.</b>If the ERB falls toward 1 standard deviation below average, the S&amp;P 500 should fall 19%, and at -2 standard deviations, the S&amp;P 500 falls 27% (Exhibit 8).</p>\n<p><img src=\"https://static.tigerbbs.com/1a4676f39d2906c38e998d09c9dbedf0\" tg-width=\"1224\" tg-height=\"407\" width=\"100%\" height=\"auto\"></p>\n<ul>\n <li><b>Second, and as discussed here most recently on Friday, consumer confidence has recently fallen sharply.</b>It started with the University of Michigan survey plummeting in August to lower levels than we witnessed during the entire pandemic and recession last year. While the Conference Board Consumer Confidence Survey remained elevated in July, it saw a big catch up to the downside in August as well. According to Wilson,<b>these surveys are important variables because they have strong positive correlations to the y/y change in the S&amp;P 500.</b>In other words,<b>based on the UMich survey, the S&amp;P 500 appears vulnerable to at least a 10-20% correction if the survey doesn't improve next month.</b></li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/848d981e38bb32e01cdf8a6becca1455\" tg-width=\"871\" tg-height=\"523\" width=\"100%\" height=\"auto\">Here, Morgan Stanley's view is that \"<b>consumers aren't as naïve as they are often made out to be</b>. They know the last year has been a bit of a bonanza working from home while receiving stimulus checks from the government that many didn't need (85% of all Americans received stimulus checks).\" Meanwhile, prices of everything are up a lot just as the extra money has stopped going out. That's a bad combo for sentiment and supports not only our stagflation thesis, but also Morgan Stanley's expectation of payback in demand view and underweight on Consumer Discretionary stocks, particularly goods-related ones.</p>\n<p>Finally, while Wilson concedes that many businesses have done extremely well during the pandemic, \"<b>the trends here are also likely to subside\"</b>and the best way to gauge the fadiing momentum in businesses will come from the Purchasing Manager Surveys. While earlier this year we reached record highs in many of the subcomponents, much like economic surprise indices and earnings revision breadth measures, the PMIs are mean reverting. Indeed, as Wilson - who used PMI data to cement his mid-cycle thesis - the peak rate of change was in April just as the PMIs peaked as well. Most importantly, as we observed previously,<b>the prices paid component (inverted) leads the headline by approximately 12 months and suggests the decline in the PMIs will likely be worse than typically witnessed during the mid-cycle transition phase – i.e., back toward 50, if not lower</b>(Exhibit 10).<b>This, as Morgan Stanley points out, would imply the Headline PMI is down 10-20% y/y by December: \"</b>Given a tight relationship with the y/y change in the S&amp;P 500, the implication is that the S&amp;P could see at least a 10-20% decline over the next 3 months (Exhibit 11).\"</p>\n<p><img src=\"https://static.tigerbbs.com/45afcf0068538b4f56bc85f42af9e52f\" tg-width=\"1233\" tg-height=\"431\" width=\"100%\" height=\"auto\">Bottom line according to Wilson, the typical \"fire\" outcome would lead to a modest and healthy 10% correction in the S&amp;P 500, but<b>\"the \"ice\" scenario is starting to look more likely, in our opinion, and could result in a more destructive and unexpected outcome.\"</b>As a result, we continue to recommend a barbell of more defensively oriented quality (Healthcare and Staples) to protect from the \"ice\" scenario while keeping a leg in Financials to participate in the \"fire\" outcome should higher rates materialize.</p>","source":"lsy1583725640930","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>\"Ice Is Coming\": Morgan Stanley Warns Odds Of \"Destructive\" 20%+ Correction Are Rising</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n\"Ice Is Coming\": Morgan Stanley Warns Odds Of \"Destructive\" 20%+ Correction Are Rising\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-21 15:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/ice-coming-morgan-stanley-warns-odds-destructive-20-correction-are-rising><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>One month ago,we saidthat when Morgan Stanley's chief equity strategist Michael Wilson hiked his year-end price target from 3,900 to 4,000,he did so very \"reluctantly\", as if someone was tapping on ...</p>\n\n<a href=\"https://www.zerohedge.com/markets/ice-coming-morgan-stanley-warns-odds-destructive-20-correction-are-rising\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","SPY":"标普500ETF"},"source_url":"https://www.zerohedge.com/markets/ice-coming-morgan-stanley-warns-odds-destructive-20-correction-are-rising","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116085013","content_text":"One month ago,we saidthat when Morgan Stanley's chief equity strategist Michael Wilson hiked his year-end price target from 3,900 to 4,000,he did so very \"reluctantly\", as if someone was tapping on his shoulder with an Uzi, because while the note was supposed to be cheerful and rosy, all Wilson could talk about was the downside scenario which included all the usual sorts of fire and brimstone.\nWell, fast forward to today when suddenly global markets are writing under the throes of Evergrande contagion sending spoos sharply below their 50DMA critical support level, and when early this morning, Michael Wilson is back in his prime as Wall Street's biggest bear, going back to his core thesis that the current Mid-cycle transition will end in either \"Fire\", i.e. a sharp market correction...\n\n... or \"Ice\", with consumer spending grinding to a halt...\n... and observes that \"the ice scenario would be worse for markets and we are leaning in that direction given the fall in consumer confidence and reset lower in PMIs we expect.\"\nBacking up a bit, for those unaware, since March, Wilson had been espoused a mid-cycle transition narrative for US Equity markets, which he says has played out to script for the most part, with large-cap quality outperforming while the average stock has materially underperformed the S&P 500, the exact opposite of what occurred during the early cycle phase of recovery.\nRelieved that he no longer has to hide his bearish views behind a facade of cheerful optimism (observed most recently during his August S&P target hike), Wilson than mocks the \"many commentators and clients\" who continue to point to the S&P 500 near all-time highs as a leading indicator and rationale for even higher prices ahead, and cautions that in his view, \"the relative strength of the S&P 500 and Nasdaq 100 is further confirmation that the market understands the mid-cycle transition narrative and has bought into it hook, line and sinker. After all, the S&P 500 is the highest quality large cap index in the world.In short, it should be outperforming right now.\"\nThe question, as Wilson puts it, whether the mid-cycle transition will end with a correction in this index as it typically does, or whether it's different this time? His prediction:\"With our year end target 10% below current levels, our view is clear: the mid-cycle transition will end with the rolling correction finally hitting the S&P 500.\"\nAnd so, for the benefit incredulous bulls who can't believe all the red they are seeing this morning, Wilson explains that \"the mid-cycle transition will end with the rolling correction finally hitting the S&P 500.\" He then reminds MS clients that he has laid out two near-term risk paths that could lead to this outcome: \"fire\" (the Fed begins to remove monetary accommodation in response to an overheating economy) and \"ice\" (earnings revisions and higher frequency macro data points decelerate amid demand pull forward, supply chain issues and margin pressure).\"\nAnd while in his weekly note he dives deeper into both of these paths and points \"to accelerating risks on both the policy and growth fronts\" the emphasis is on the \"Ice\" scenario which could result in \"a mode destructive outcome, i.e., a 20%+ correction.\"Here's why:\nThe typical mid-cycle \"fire\" outcome would lead to a modest and healthy 10% correction in the S&P 500.However, the \"ice\" scenario is starting to look more likely, and could result in a more destructive outcome – i.e. a 20%+ correction.As a result, we continue to recommend a barbell of more defensively oriented quality (Healthcare and Staples) to protect from the \"ice\" scenario while keeping a leg in Financials to participate in the \"fire\" outcome as higher rates materialize.\nThe next question is what would catalyze the upcoming correction, whether it is the 10% \"fire\" or 20% \"ice\" drop. Wilson responds:\n\n We have presented two potential scenarios for why / how the correction will ensue. The more traditional ending to a mid-cycle transition is a \"fire\" outcome whereby the recovery overheats and the Fed begins to remove accommodation. In the 1994 and 2004 transitions, that meant raising the Fed Funds Rate. In 2011, it was simply the ending of QE2.\n This time we think it is the tapering of asset purchases later this year/early next year.Given that the taper was effectively pre-announced at Jackson Hole 3 weeks ago, is it a coincidence that equity markets have been softer in September? Under this scenario, the economy reaccelerates from the summer slowdown but not enough to offset the tightening of financial conditions from higher back end rates and less liquidity in the system. In addition to the anticipated tapering of asset purchases later this year, we point to the fact that the Treasury's General Account (TGA) has fallen by $1T since March (Exhibit 3).\n\n\nWhile this has been a good offset to the decelerating M2 growth (Exhibit 4), that offset is probably finished now. Bottom line, this is the time of the mid cycle transition when P/Es for the broader index properly contract (Exhibit 5).\n\nPiling on the pessimism, Wilson then notes that \"there are several key variables we are monitoring that currently support a view for a worse than expected growth deceleration.\"\n\nFirst is NTM earnings estimates.Even if the economy rebounds in 4Q from the slowdown this summer, it likely won't translate into higher earnings estimates as incremental margins rollover due to higher costs and taxes. This is the mirror image of the past year when costs were being eliminated as revenues benefitted greatly from the fiscal stimulus. Indeed, NTM EPS estimates for the S&P 500 appear to have been flattening out over the past month after a record recovery to levels that are 20% above the prior peak (Exhibit 6). This will be critical to watch as we enter 3Q earnings season and companies update investors on costs/margins and potential payback in demand from the consumption binge earlier this year.\n\nAnother way to analyze this rate of change on earnings momentum is to look atearnings revision breadth (or ERB), which Wilson thinks is vulnerable to a simple reversion to the mean from today's very elevated levels of +2 standard deviations (Exhibit 7).If earnings revision breadth (ERB) normalizes to its average over the next 3 months, the S&P should fall approximately 11%.If the ERB falls toward 1 standard deviation below average, the S&P 500 should fall 19%, and at -2 standard deviations, the S&P 500 falls 27% (Exhibit 8).\n\n\nSecond, and as discussed here most recently on Friday, consumer confidence has recently fallen sharply.It started with the University of Michigan survey plummeting in August to lower levels than we witnessed during the entire pandemic and recession last year. While the Conference Board Consumer Confidence Survey remained elevated in July, it saw a big catch up to the downside in August as well. According to Wilson,these surveys are important variables because they have strong positive correlations to the y/y change in the S&P 500.In other words,based on the UMich survey, the S&P 500 appears vulnerable to at least a 10-20% correction if the survey doesn't improve next month.\n\nHere, Morgan Stanley's view is that \"consumers aren't as naïve as they are often made out to be. They know the last year has been a bit of a bonanza working from home while receiving stimulus checks from the government that many didn't need (85% of all Americans received stimulus checks).\" Meanwhile, prices of everything are up a lot just as the extra money has stopped going out. That's a bad combo for sentiment and supports not only our stagflation thesis, but also Morgan Stanley's expectation of payback in demand view and underweight on Consumer Discretionary stocks, particularly goods-related ones.\nFinally, while Wilson concedes that many businesses have done extremely well during the pandemic, \"the trends here are also likely to subside\"and the best way to gauge the fadiing momentum in businesses will come from the Purchasing Manager Surveys. While earlier this year we reached record highs in many of the subcomponents, much like economic surprise indices and earnings revision breadth measures, the PMIs are mean reverting. Indeed, as Wilson - who used PMI data to cement his mid-cycle thesis - the peak rate of change was in April just as the PMIs peaked as well. Most importantly, as we observed previously,the prices paid component (inverted) leads the headline by approximately 12 months and suggests the decline in the PMIs will likely be worse than typically witnessed during the mid-cycle transition phase – i.e., back toward 50, if not lower(Exhibit 10).This, as Morgan Stanley points out, would imply the Headline PMI is down 10-20% y/y by December: \"Given a tight relationship with the y/y change in the S&P 500, the implication is that the S&P could see at least a 10-20% decline over the next 3 months (Exhibit 11).\"\nBottom line according to Wilson, the typical \"fire\" outcome would lead to a modest and healthy 10% correction in the S&P 500, but\"the \"ice\" scenario is starting to look more likely, in our opinion, and could result in a more destructive and unexpected outcome.\"As a result, we continue to recommend a barbell of more defensively oriented quality (Healthcare and Staples) to protect from the \"ice\" scenario while keeping a leg in Financials to participate in the \"fire\" outcome should higher rates materialize.","news_type":1},"isVote":1,"tweetType":1,"viewCount":333,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860717806,"gmtCreate":1632212546606,"gmtModify":1676530726200,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/860717806","repostId":"1141548942","repostType":4,"repost":{"id":"1141548942","pubTimestamp":1632210732,"share":"https://www.laohu8.com/m/news/1141548942?lang=&edition=full","pubTime":"2021-09-21 15:52","market":"us","language":"en","title":"Boeing Stock: The Bullish Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1141548942","media":"Seeking Alpha","summary":"Summary\n\nSingle aisle aircraft forecast exceeds pre-pandemic levels.\nProjections for wide body aircr","content":"<p><b>Summary</b></p>\n<ul>\n <li>Single aisle aircraft forecast exceeds pre-pandemic levels.</li>\n <li>Projections for wide body aircraft are still down 8% compared to pre-pandemic levels.</li>\n <li>The long-term trend remains directed upward.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b350943f97fd9c0222325dc4e2f24be1\" tg-width=\"1536\" tg-height=\"927\" referrerpolicy=\"no-referrer\"><span>Stephen Brashear/Getty Images News</span></p>\n<p>Boeing(NYSE:BA)&nbsp;has provided its 20-year commercial market outlook on the 14thof September. Last year Boeing provided the outlook in early October and it was extremely interesting outlook to analyze and it showed the expected impact on demand for commercial aircraft. At this time last year, airlines had tried to bring their capacities back to 50%-70% after cutting it by 90% in Q1 2020. With vaccines rolled out, there has been some optimism regarding the pace of the recovery though revenue passenger-kilometers are still expected to be down around 60% in 2021.</p>\n<p>So, with the new projections available it's interesting to see how the realities of RPKs still being down around 60%, but with vaccinations programs underway, affects the projections for aircraft deliveries. The commercial market outlooks always contain a lot of information, so it's likely we will be spending numerous reports on this subject. In this report, we will focus on several subjects in particular. Those are the demand profile by aircraft body type and how those have changed with respect to last year in the 20-year frame. Additionally, we also will be considering to the 10-year frame as it gives an idea whether progress has been made such that projections are trending up again for the 10-year period.</p>\n<p><b>Boeing expects equal weight value recovery</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/04386b75b027b62564361d89fe7d498f\" tg-width=\"640\" tg-height=\"372\" referrerpolicy=\"no-referrer\"><span>Figure 1: Commercial Market Outlook Boeing 2020 and 2021 (Source: AeroAnalysis)</span></p>\n<p>Figure 1 provides a tiny bit of context on how the 20-year forecast has developed since last year. Overall, the outlook has increased by 500 units from 43,110 expected deliveries to 43,610. That number is still down 430 units from the 2019 CMO, which we consider a baseline that Boeing and the industry would want to return to. So, what does the number mean? With over half of the decline compared to the baseline being recaptured in this year’s outlook, Boeing seems to be expecting a very fast market recovery for aircraft.</p>\n<p>Late 2024 is what Cirium, a data analytics provider for the aviation industry, is using as their baseline, and Boeing seems to be expecting a stronger recovery that's in line with expectations from IATA. Following the path from small aircraft to bigger aircraft, Boeing expects the recovery to be completed by 2023-2024. So, Boeing is expecting the recovery to take at least a year less.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/14eebcedb640b76fe8af7b3f979de273\" tg-width=\"640\" tg-height=\"221\" referrerpolicy=\"no-referrer\"><span>Source: Boeing</span></p>\n<p>With that assumption comes a downward revision of 40 units for regional jet deliveries. The longer the recovery takes, the more prominent the role of the regional jets would be. While Boeing’s assumptions on the recovery have not changed drastically, it seems that optimism on the recovery trajectory goes at the expense of regional jet forecasts as using bigger planes might becoming more compelling once again. Single aisle delivery forecasts were hiked by 390 units covering nearly 80% of the hike compared to last year. It seems like a huge deal, but one should consider that on monthly production levels it equates to slightly more than 1.5 aircraft, and assuming a perfect split between Boeing and Airbus which is optimistic this would mean that new projections support the delivery of roughly one additional single aisle jet per month. So, a big increase in absolute numbers but in relative sense it is very small around 1%. What's more interesting is that the outlook for single aisle aircraft already is above the 2019 levels.</p>\n<p>More interesting to look at is what happened to wide body projections. Last year the projections for wide body aircraft deliveries were dropped by 10%. This year, it is up by 190 units. Given that a widebody aircraft sells for 2-3 times the value of a single aisle jet, we can conclude that in terms of value the wide body passenger aircraft and single aisle aircraft have equal contributions to the hiked forecast but wide body deliveries remain down 8% from the baseline. What also should be considered is that around 360 aircraft wide body aircraft have been retired early according to our own research. With that in mind, one would have hoped for a stronger hike in the expected wide body deliveries. So, the wide body market is really showing that full recovery is still going to take a while but it should also be mentioned that the current projections leave a lot of room for increases in production rates on the wide body programs.</p>\n<p>For the wide body freighter market, the forecast was reduced by 40 units year-over-year and that's interesting because worldwide we're seeing issues with logistics. But it seems that the dedicated freighter market is not expected to benefit over the longer term. There are two explanations for that. The first one is that as international wide body traffic recovers, belly cargo capacity will come online again, and the second explanation is that some passenger aircraft have been converted for freighter services permanently. So, Boeing’s strength in the converted freighter market is biting the company back in the dedicated freighter market.</p>\n<p><b>Boeing's delivery profile remains backloaded</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/91b6dd9a113b82957533ee723e1d143c\" tg-width=\"631\" tg-height=\"543\" referrerpolicy=\"no-referrer\"><span>Source: Boeing</span></p>\n<p>What remains interesting to highlight are the 10-year delivery outlooks. The baseline 10-year outlook has not been specified by Boeing but the airline did say that the 18,350 aircraft deliveries expected over a decade were down 11% compared to the baseline which led to&nbsp;our conclusion&nbsp;that the pandemic will be resulting in a 11% adverse impact over a decade, which is substantial. This year, Boeing expects the 10-year delivery numbers to total 19,330 units marking a 5% increase driven by higher single aisle deliveries (+800) and higher wide body deliveries (+180). Those numbers were expected to be better, signaling the recovery in production and delivery rates with an important role for the Boeing 737 MAX production and delivery ramp and a release of wide body aircraft from inventory. So, the 10-year rolling number improving is not so much related to turning more bullish on the recovery but more that a year with low delivery volumes (last year) disappearing from the rolling number and a year with more deliveries replacing it. So, we cannot say that recovery is accelerating beyond what was earlier thought. Thisalso isdemonstrated by the rise in the 10-year forecasts being 980 units vs. a 500 unit hike in the 20-year forecast.</p>\n<p>So, the numbers are moving in the positive direction. However, what we also have observed is that the delivery profile remains backloaded. In 2019, around 47% of the deliveries were expected in the first half of the 20-year outlook and in 2020 this reduced to 43% only to bump up modestly to 44% in the most recent outlook. Freighters and regional jets are the exception to that trend as reduced demand in the near term somewhat has strengthened the use case for regional jets and the disappearance of belly capacity on wide body aircraft vanished when international passenger transport was reduced significantly, resulting in an uptick in demand for freighter aircraft. While Boeing has had its fair share of headwinds over the past years, the backlog which is visualized in the&nbsp;TAF Boeing Backlog Monitor&nbsp;shows that the jet maker has thousands of aircraft in the order books and more to come in the coming years.</p>\n<p><b>Conclusion</b></p>\n<p>What we're seeing is that Boeing is expecting a return to pre-pandemic conditions roughly a year earlier than some data analytics companies and possibly that's also what Michael O’Leary from Ryanair hinted on when he&nbsp;said&nbsp;he did not share Boeing’s optimistic pricing scenario which without doubt is related to forecast demand. What's most striking to me in the CMO is that wide body demand forecasts are still at a level where I would say investing in Boeing as well Airbus is a no-brainer. Boeing’s forecasts tend to be conservative, so in my view while I'm often critical on Being I do think that for long-term investors there's a lot of reason to invest or remain invested in Boeing as well as Airbus.</p>\n<p>While it seems that Boeing is more positive about the future, it should be noted that the 20-year outlooks are rolling numbers so last year was a year with lower deliveries and in this year’s outlook that year is obviously replaced with a production year 19 years from now when production is expected to be good. So, it's very important to keep in mind that higher anticipated deliveries are not necessarily an indication that recovery timelines have accelerated. However, what the numbers in my view do show is that the commercial aircraft industry is very resilient and for Boeing the art will be to capitalize on the long-term trend and resilience by developing appropriate products.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boeing Stock: The Bullish Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoeing Stock: The Bullish Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-21 15:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4455910-boeing-stock-the-bullish-outlook><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nSingle aisle aircraft forecast exceeds pre-pandemic levels.\nProjections for wide body aircraft are still down 8% compared to pre-pandemic levels.\nThe long-term trend remains directed upward.\n...</p>\n\n<a href=\"https://seekingalpha.com/article/4455910-boeing-stock-the-bullish-outlook\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BA":"波音"},"source_url":"https://seekingalpha.com/article/4455910-boeing-stock-the-bullish-outlook","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141548942","content_text":"Summary\n\nSingle aisle aircraft forecast exceeds pre-pandemic levels.\nProjections for wide body aircraft are still down 8% compared to pre-pandemic levels.\nThe long-term trend remains directed upward.\n\nStephen Brashear/Getty Images News\nBoeing(NYSE:BA) has provided its 20-year commercial market outlook on the 14thof September. Last year Boeing provided the outlook in early October and it was extremely interesting outlook to analyze and it showed the expected impact on demand for commercial aircraft. At this time last year, airlines had tried to bring their capacities back to 50%-70% after cutting it by 90% in Q1 2020. With vaccines rolled out, there has been some optimism regarding the pace of the recovery though revenue passenger-kilometers are still expected to be down around 60% in 2021.\nSo, with the new projections available it's interesting to see how the realities of RPKs still being down around 60%, but with vaccinations programs underway, affects the projections for aircraft deliveries. The commercial market outlooks always contain a lot of information, so it's likely we will be spending numerous reports on this subject. In this report, we will focus on several subjects in particular. Those are the demand profile by aircraft body type and how those have changed with respect to last year in the 20-year frame. Additionally, we also will be considering to the 10-year frame as it gives an idea whether progress has been made such that projections are trending up again for the 10-year period.\nBoeing expects equal weight value recovery\nFigure 1: Commercial Market Outlook Boeing 2020 and 2021 (Source: AeroAnalysis)\nFigure 1 provides a tiny bit of context on how the 20-year forecast has developed since last year. Overall, the outlook has increased by 500 units from 43,110 expected deliveries to 43,610. That number is still down 430 units from the 2019 CMO, which we consider a baseline that Boeing and the industry would want to return to. So, what does the number mean? With over half of the decline compared to the baseline being recaptured in this year’s outlook, Boeing seems to be expecting a very fast market recovery for aircraft.\nLate 2024 is what Cirium, a data analytics provider for the aviation industry, is using as their baseline, and Boeing seems to be expecting a stronger recovery that's in line with expectations from IATA. Following the path from small aircraft to bigger aircraft, Boeing expects the recovery to be completed by 2023-2024. So, Boeing is expecting the recovery to take at least a year less.\nSource: Boeing\nWith that assumption comes a downward revision of 40 units for regional jet deliveries. The longer the recovery takes, the more prominent the role of the regional jets would be. While Boeing’s assumptions on the recovery have not changed drastically, it seems that optimism on the recovery trajectory goes at the expense of regional jet forecasts as using bigger planes might becoming more compelling once again. Single aisle delivery forecasts were hiked by 390 units covering nearly 80% of the hike compared to last year. It seems like a huge deal, but one should consider that on monthly production levels it equates to slightly more than 1.5 aircraft, and assuming a perfect split between Boeing and Airbus which is optimistic this would mean that new projections support the delivery of roughly one additional single aisle jet per month. So, a big increase in absolute numbers but in relative sense it is very small around 1%. What's more interesting is that the outlook for single aisle aircraft already is above the 2019 levels.\nMore interesting to look at is what happened to wide body projections. Last year the projections for wide body aircraft deliveries were dropped by 10%. This year, it is up by 190 units. Given that a widebody aircraft sells for 2-3 times the value of a single aisle jet, we can conclude that in terms of value the wide body passenger aircraft and single aisle aircraft have equal contributions to the hiked forecast but wide body deliveries remain down 8% from the baseline. What also should be considered is that around 360 aircraft wide body aircraft have been retired early according to our own research. With that in mind, one would have hoped for a stronger hike in the expected wide body deliveries. So, the wide body market is really showing that full recovery is still going to take a while but it should also be mentioned that the current projections leave a lot of room for increases in production rates on the wide body programs.\nFor the wide body freighter market, the forecast was reduced by 40 units year-over-year and that's interesting because worldwide we're seeing issues with logistics. But it seems that the dedicated freighter market is not expected to benefit over the longer term. There are two explanations for that. The first one is that as international wide body traffic recovers, belly cargo capacity will come online again, and the second explanation is that some passenger aircraft have been converted for freighter services permanently. So, Boeing’s strength in the converted freighter market is biting the company back in the dedicated freighter market.\nBoeing's delivery profile remains backloaded\nSource: Boeing\nWhat remains interesting to highlight are the 10-year delivery outlooks. The baseline 10-year outlook has not been specified by Boeing but the airline did say that the 18,350 aircraft deliveries expected over a decade were down 11% compared to the baseline which led to our conclusion that the pandemic will be resulting in a 11% adverse impact over a decade, which is substantial. This year, Boeing expects the 10-year delivery numbers to total 19,330 units marking a 5% increase driven by higher single aisle deliveries (+800) and higher wide body deliveries (+180). Those numbers were expected to be better, signaling the recovery in production and delivery rates with an important role for the Boeing 737 MAX production and delivery ramp and a release of wide body aircraft from inventory. So, the 10-year rolling number improving is not so much related to turning more bullish on the recovery but more that a year with low delivery volumes (last year) disappearing from the rolling number and a year with more deliveries replacing it. So, we cannot say that recovery is accelerating beyond what was earlier thought. Thisalso isdemonstrated by the rise in the 10-year forecasts being 980 units vs. a 500 unit hike in the 20-year forecast.\nSo, the numbers are moving in the positive direction. However, what we also have observed is that the delivery profile remains backloaded. In 2019, around 47% of the deliveries were expected in the first half of the 20-year outlook and in 2020 this reduced to 43% only to bump up modestly to 44% in the most recent outlook. Freighters and regional jets are the exception to that trend as reduced demand in the near term somewhat has strengthened the use case for regional jets and the disappearance of belly capacity on wide body aircraft vanished when international passenger transport was reduced significantly, resulting in an uptick in demand for freighter aircraft. While Boeing has had its fair share of headwinds over the past years, the backlog which is visualized in the TAF Boeing Backlog Monitor shows that the jet maker has thousands of aircraft in the order books and more to come in the coming years.\nConclusion\nWhat we're seeing is that Boeing is expecting a return to pre-pandemic conditions roughly a year earlier than some data analytics companies and possibly that's also what Michael O’Leary from Ryanair hinted on when he said he did not share Boeing’s optimistic pricing scenario which without doubt is related to forecast demand. What's most striking to me in the CMO is that wide body demand forecasts are still at a level where I would say investing in Boeing as well Airbus is a no-brainer. Boeing’s forecasts tend to be conservative, so in my view while I'm often critical on Being I do think that for long-term investors there's a lot of reason to invest or remain invested in Boeing as well as Airbus.\nWhile it seems that Boeing is more positive about the future, it should be noted that the 20-year outlooks are rolling numbers so last year was a year with lower deliveries and in this year’s outlook that year is obviously replaced with a production year 19 years from now when production is expected to be good. So, it's very important to keep in mind that higher anticipated deliveries are not necessarily an indication that recovery timelines have accelerated. However, what the numbers in my view do show is that the commercial aircraft industry is very resilient and for Boeing the art will be to capitalize on the long-term trend and resilience by developing appropriate products.","news_type":1},"isVote":1,"tweetType":1,"viewCount":264,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860717091,"gmtCreate":1632212532513,"gmtModify":1676530726192,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/860717091","repostId":"1183568849","repostType":4,"isVote":1,"tweetType":1,"viewCount":188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860714422,"gmtCreate":1632212523966,"gmtModify":1676530726202,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860714422","repostId":"1151068672","repostType":4,"repost":{"id":"1151068672","pubTimestamp":1632211514,"share":"https://www.laohu8.com/m/news/1151068672?lang=&edition=full","pubTime":"2021-09-21 16:05","market":"us","language":"en","title":"AstraZeneca to Build New Manufacturing Facility in Ireland","url":"https://stock-news.laohu8.com/highlight/detail?id=1151068672","media":"Bloomberg","summary":"AstraZeneca Plc will invest $360 million building a new manufacturing facility for small molecules i","content":"<p>AstraZeneca Plc&nbsp;will invest $360 million building a new manufacturing facility for small molecules in Dublin, in a blow to U.K. hopes that the drugmaker would develop the site in its domestic market.</p>\n<p>The new plant will ensure that Astra’s global supply network is “fit for future growth” and will rapidly meet the needs of its new medicines pipeline, the company said in a&nbsp;statement&nbsp;on Tuesday.</p>\n<p>The facility will be located at the Alexion campus in College Park, Dublin, and will create 100 highly skilled jobs in the life sciences sector. Astra said the project will also provide an important boost to the local economy. The deal will “nurture the country’s life sciences sector and allow for the development of high value-added medicines,” Chief Executive Officer Pascal Soriot said.</p>\n<p>News of the Irish investment comes only a few days after the U.K. government said it would rely on vaccines from Pfizer Inc. and Moderna Inc. for its Covid-19 booster program,sideliningthe homegrown shot from Astra.</p>\n<p></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca to Build New Manufacturing Facility in Ireland</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca to Build New Manufacturing Facility in Ireland\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-21 16:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-09-21/astrazeneca-to-build-new-manufacturing-facility-in-ireland?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AstraZeneca Plc will invest $360 million building a new manufacturing facility for small molecules in Dublin, in a blow to U.K. hopes that the drugmaker would develop the site in its domestic market.\n...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-09-21/astrazeneca-to-build-new-manufacturing-facility-in-ireland?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","AZN.UK":"阿斯利康制药"},"source_url":"https://www.bloomberg.com/news/articles/2021-09-21/astrazeneca-to-build-new-manufacturing-facility-in-ireland?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151068672","content_text":"AstraZeneca Plc will invest $360 million building a new manufacturing facility for small molecules in Dublin, in a blow to U.K. hopes that the drugmaker would develop the site in its domestic market.\nThe new plant will ensure that Astra’s global supply network is “fit for future growth” and will rapidly meet the needs of its new medicines pipeline, the company said in a statement on Tuesday.\nThe facility will be located at the Alexion campus in College Park, Dublin, and will create 100 highly skilled jobs in the life sciences sector. Astra said the project will also provide an important boost to the local economy. The deal will “nurture the country’s life sciences sector and allow for the development of high value-added medicines,” Chief Executive Officer Pascal Soriot said.\nNews of the Irish investment comes only a few days after the U.K. government said it would rely on vaccines from Pfizer Inc. and Moderna Inc. for its Covid-19 booster program,sideliningthe homegrown shot from Astra.","news_type":1},"isVote":1,"tweetType":1,"viewCount":105,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860714641,"gmtCreate":1632212511983,"gmtModify":1676530726192,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/860714641","repostId":"1160840483","repostType":4,"isVote":1,"tweetType":1,"viewCount":220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860715570,"gmtCreate":1632212451890,"gmtModify":1676530726175,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CPNG\">$Coupang, Inc.(CPNG)$</a>$$$$","listText":"<a href=\"https://laohu8.com/S/CPNG\">$Coupang, Inc.(CPNG)$</a>$$$$","text":"$Coupang, Inc.(CPNG)$$$$$","images":[{"img":"https://static.tigerbbs.com/86bb74e46b1bf47cc893679d931cad98","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860715570","isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":860979715,"gmtCreate":1632127982537,"gmtModify":1676530706306,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>$$$$","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>$$$$","text":"$NIO Inc.(NIO)$$$$$","images":[{"img":"https://static.tigerbbs.com/81a9989f55e4eca08eee8761371369c0","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860979715","isVote":1,"tweetType":1,"viewCount":114,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":887993886,"gmtCreate":1631953079045,"gmtModify":1676530677480,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/887993886","repostId":"2168717845","repostType":4,"repost":{"id":"2168717845","pubTimestamp":1631930700,"share":"https://www.laohu8.com/m/news/2168717845?lang=&edition=full","pubTime":"2021-09-18 10:05","market":"us","language":"en","title":"Endurance Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2168717845","media":"Business Wire","summary":"NEW YORK, September 17, 2021--(BUSINESS WIRE)--Endurance Acquisition Corp. (the \"Company\") announced","content":"<p><b>NEW YORK, September 17, 2021</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/EDNCU\">Endurance Acquisition Corp.</a> (the \"Company\") announced today that it closed its initial public offering of 20,000,000 units at $10.00 per unit. The gross proceeds from the offering were $200 million before deducting underwriting discounts and estimated offering expenses. The units began trading on the Nasdaq Capital Market under the ticker symbol \"EDNCU\" on September 15, 2021. Each unit consists of <a href=\"https://laohu8.com/S/AONE.U\">one</a> Class A ordinary share of the Company and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment. Only whole warrants are exercisable. Once the securities comprising the units begin separate trading, the Class A ordinary shares and redeemable warrants are expected to be listed on the Nasdaq Capital Market under the symbols \"EDNC\" and \"EDNCW,\" respectively.</p>\n<p>Endurance Acquisition Corp. is a blank check company, incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or assets. The Company intends to focus its search for a target business operating in data infrastructure and analytics, with a primary focus on space and wireless industries and related technology and services, or \"space-based tech\" businesses. These businesses can be found across the platforms and sensors, mobile communications, Internet of Things and artificial intelligence and big data analytics sectors.</p>\n<p>Cantor Fitzgerald &amp; Co acted as sole book-running manager for the offering. Truist Securities acted as lead manager for the offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 3,000,000 units at the initial public offering price to cover over-allotments, if any.</p>\n<p>The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from Cantor Fitzgerald &amp; Co., Attn: Capital Markets, 499 Park Avenue, 5th Floor New York, New York 10022, Email: prospectus@cantor.com.</p>\n<p>The registration statement relating to the securities became effective on September 14, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>\n<p><b>Forward-Looking Statements</b></p>\n<p>This press release contains statements that constitute \"forward-looking statements,\" including with respect to the anticipated use of the net proceeds, the Company’s approach to and the types of businesses the Company will focus on in its search to identify a target it its initial business combination. No assurance can be given that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the \"Risk Factors\" section of the Company’s prospectus relating to the offering filed with the U.S. Securities and Exchange Commission (the \"SEC\"). Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.</p>\n<p><b>About Endurance Acquisition Corp.</b></p>\n<p>Endurance Acquisition Corp. is a blank check company, incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or assets. The Company intends to focus its search for a target business operating in data infrastructure and analytics, with a primary focus on space and wireless industries and related technology and services, or \"space-based tech\" businesses. The Company plans to leverage its management team’s, directors’, advisors’ and sponsor’s extensive experience across its target sectors to seek to identify attractive initial business combination opportunities.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Endurance Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEndurance Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 10:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/endurance-acquisition-corp-announces-closing-200500673.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, September 17, 2021--(BUSINESS WIRE)--Endurance Acquisition Corp. (the \"Company\") announced today that it closed its initial public offering of 20,000,000 units at $10.00 per unit. The gross ...</p>\n\n<a href=\"https://finance.yahoo.com/news/endurance-acquisition-corp-announces-closing-200500673.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/endurance-acquisition-corp-announces-closing-200500673.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2168717845","content_text":"NEW YORK, September 17, 2021--(BUSINESS WIRE)--Endurance Acquisition Corp. (the \"Company\") announced today that it closed its initial public offering of 20,000,000 units at $10.00 per unit. The gross proceeds from the offering were $200 million before deducting underwriting discounts and estimated offering expenses. The units began trading on the Nasdaq Capital Market under the ticker symbol \"EDNCU\" on September 15, 2021. Each unit consists of one Class A ordinary share of the Company and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment. Only whole warrants are exercisable. Once the securities comprising the units begin separate trading, the Class A ordinary shares and redeemable warrants are expected to be listed on the Nasdaq Capital Market under the symbols \"EDNC\" and \"EDNCW,\" respectively.\nEndurance Acquisition Corp. is a blank check company, incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or assets. The Company intends to focus its search for a target business operating in data infrastructure and analytics, with a primary focus on space and wireless industries and related technology and services, or \"space-based tech\" businesses. These businesses can be found across the platforms and sensors, mobile communications, Internet of Things and artificial intelligence and big data analytics sectors.\nCantor Fitzgerald & Co acted as sole book-running manager for the offering. Truist Securities acted as lead manager for the offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 3,000,000 units at the initial public offering price to cover over-allotments, if any.\nThe offering was made only by means of a prospectus. Copies of the prospectus may be obtained from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 5th Floor New York, New York 10022, Email: prospectus@cantor.com.\nThe registration statement relating to the securities became effective on September 14, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nForward-Looking Statements\nThis press release contains statements that constitute \"forward-looking statements,\" including with respect to the anticipated use of the net proceeds, the Company’s approach to and the types of businesses the Company will focus on in its search to identify a target it its initial business combination. No assurance can be given that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the \"Risk Factors\" section of the Company’s prospectus relating to the offering filed with the U.S. Securities and Exchange Commission (the \"SEC\"). Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.\nAbout Endurance Acquisition Corp.\nEndurance Acquisition Corp. is a blank check company, incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or assets. The Company intends to focus its search for a target business operating in data infrastructure and analytics, with a primary focus on space and wireless industries and related technology and services, or \"space-based tech\" businesses. The Company plans to leverage its management team’s, directors’, advisors’ and sponsor’s extensive experience across its target sectors to seek to identify attractive initial business combination opportunities.","news_type":1},"isVote":1,"tweetType":1,"viewCount":312,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887993319,"gmtCreate":1631953067731,"gmtModify":1676530677642,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/887993319","repostId":"1197410423","repostType":4,"repost":{"id":"1197410423","pubTimestamp":1631932844,"share":"https://www.laohu8.com/m/news/1197410423?lang=&edition=full","pubTime":"2021-09-18 10:40","market":"us","language":"en","title":"HLBZ Stock: What to Know as Little-Known Helbiz Rockets Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=1197410423","media":"investorplace","summary":"One of the fastest-moving stocks today is Helbiz(NASDAQ:HLBZ). Indeed, today’s price action in HLBZ ","content":"<p>One of the fastest-moving stocks today is&nbsp;<b>Helbiz</b>(NASDAQ:<b><u>HLBZ</u></b>). Indeed, today’s price action in HLBZ stock has been incredible to see, with shares of this micro-mobility company skyrocketing more than 140% at the time of writing.</p>\n<p>This is yet another de-SPAC company that recently closed its merger on Aug. 13. Since then, shares went from the $10 IPO price level to the $6 per share level. However, today’s price action has driven shares of HLBZ stock to more than $25 per share, representing a 4-bagger from lows seen just a few weeks ago.</p>\n<p>Post-SPAC merger volatility has certainly been the norm of late. However, for Helbiz and its de-SPAC peers, most of this volatility has been to the downside. Let’s dive into what is driving HLBZ stock higher today.</p>\n<p>HLBZ Stock Surging on Media Rights Deal</p>\n<p>Most folks know of Helbiz as a global leader in the&nbsp;micro-mobility market. You know, scooters and other various forms of car-free transportation to get around big cities.</p>\n<p>However, Helbiz is also a company looking to make waves in the streaming and entertainment space. Via its subsidiary Helbiz Media, the company has&nbsp;announced&nbsp;today a key partnership that could spur a tremendous amount of growth from here.</p>\n<p>This partnership is between Helbiz Media and&nbsp;<b>FOX Networks Group</b>&nbsp;to broadcast the Italian Series B championship in the U.S. and Caribbean. Perhaps a smaller deal relative to the rest of the streaming space, this three-year contract could provide Helbiz with some nice momentum in a niche market for sports streaming.</p>\n<p>For now, it appears investors like the way Helbiz’s management team is positioning the company. Whether or not this valuation can be maintained remains to be seen. However, today’s impressive upward spike in HLBZ stock is certainly worth watching.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HLBZ Stock: What to Know as Little-Known Helbiz Rockets Higher</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHLBZ Stock: What to Know as Little-Known Helbiz Rockets Higher\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 10:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/hlbz-stock-what-to-know-as-little-known-helbiz-rockets-higher/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>One of the fastest-moving stocks today is Helbiz(NASDAQ:HLBZ). Indeed, today’s price action in HLBZ stock has been incredible to see, with shares of this micro-mobility company skyrocketing more than ...</p>\n\n<a href=\"https://investorplace.com/2021/09/hlbz-stock-what-to-know-as-little-known-helbiz-rockets-higher/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/09/hlbz-stock-what-to-know-as-little-known-helbiz-rockets-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197410423","content_text":"One of the fastest-moving stocks today is Helbiz(NASDAQ:HLBZ). Indeed, today’s price action in HLBZ stock has been incredible to see, with shares of this micro-mobility company skyrocketing more than 140% at the time of writing.\nThis is yet another de-SPAC company that recently closed its merger on Aug. 13. Since then, shares went from the $10 IPO price level to the $6 per share level. However, today’s price action has driven shares of HLBZ stock to more than $25 per share, representing a 4-bagger from lows seen just a few weeks ago.\nPost-SPAC merger volatility has certainly been the norm of late. However, for Helbiz and its de-SPAC peers, most of this volatility has been to the downside. Let’s dive into what is driving HLBZ stock higher today.\nHLBZ Stock Surging on Media Rights Deal\nMost folks know of Helbiz as a global leader in the micro-mobility market. You know, scooters and other various forms of car-free transportation to get around big cities.\nHowever, Helbiz is also a company looking to make waves in the streaming and entertainment space. Via its subsidiary Helbiz Media, the company has announced today a key partnership that could spur a tremendous amount of growth from here.\nThis partnership is between Helbiz Media and FOX Networks Group to broadcast the Italian Series B championship in the U.S. and Caribbean. Perhaps a smaller deal relative to the rest of the streaming space, this three-year contract could provide Helbiz with some nice momentum in a niche market for sports streaming.\nFor now, it appears investors like the way Helbiz’s management team is positioning the company. Whether or not this valuation can be maintained remains to be seen. However, today’s impressive upward spike in HLBZ stock is certainly worth watching.","news_type":1},"isVote":1,"tweetType":1,"viewCount":53,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887999218,"gmtCreate":1631953055334,"gmtModify":1676530677465,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/887999218","repostId":"1128389145","repostType":4,"isVote":1,"tweetType":1,"viewCount":25,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887999173,"gmtCreate":1631953026592,"gmtModify":1676530677457,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/887999173","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","pubTimestamp":1631950800,"share":"https://www.laohu8.com/m/news/2168957763?lang=&edition=full","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research &amp; Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication &amp; Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887999328,"gmtCreate":1631953014864,"gmtModify":1676530677457,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/887999328","repostId":"2168716185","repostType":4,"repost":{"id":"2168716185","pubTimestamp":1631916051,"share":"https://www.laohu8.com/m/news/2168716185?lang=&edition=full","pubTime":"2021-09-18 06:00","market":"us","language":"en","title":"Wall Street closes rollercoaster week sharply lower","url":"https://stock-news.laohu8.com/highlight/detail?id=2168716185","media":"The Straits Times","summary":"NEW YORK  - US stocks ended sharply lower in a broad sell-off on Friday , ending a week buffeted by strong economic data, corporate tax hike worries, the Delta Covid-19 variant, and possible shifts in the US Federal Reserve's timeline for tapering asset purchases.All three major US stock indexes lost ground, with the Nasdaq Composite Index's weighed down as rising US Treasury yields pressured market-leading growth stocks.They also posted weekly losses, with the S&P index suffering its biggest tw","content":"<div>\n<p>NEW YORK (REUTERS) - US stocks ended sharply lower in a broad sell-off on Friday (Sept 17), ending a week buffeted by strong economic data, corporate tax hike worries, the Delta Covid-19 variant, and ...</p>\n\n<a href=\"http://www.straitstimes.com/business/companies-markets/wall-street-closes-rollercoaster-week-sharply-lower\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street closes rollercoaster week sharply lower</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street closes rollercoaster week sharply lower\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 06:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/business/companies-markets/wall-street-closes-rollercoaster-week-sharply-lower><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (REUTERS) - US stocks ended sharply lower in a broad sell-off on Friday (Sept 17), ending a week buffeted by strong economic data, corporate tax hike worries, the Delta Covid-19 variant, and ...</p>\n\n<a href=\"http://www.straitstimes.com/business/companies-markets/wall-street-closes-rollercoaster-week-sharply-lower\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","IVV":"标普500指数ETF","SPXU":"三倍做空标普500ETF","OEF":"标普100指数ETF-iShares","SDS":"两倍做空标普500ETF","UPRO":"三倍做多标普500ETF","SSO":"两倍做多标普500ETF","OEX":"标普100",".SPX":"S&P 500 Index","SH":"标普500反向ETF"},"source_url":"http://www.straitstimes.com/business/companies-markets/wall-street-closes-rollercoaster-week-sharply-lower","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168716185","content_text":"NEW YORK (REUTERS) - US stocks ended sharply lower in a broad sell-off on Friday (Sept 17), ending a week buffeted by strong economic data, corporate tax hike worries, the Delta Covid-19 variant, and possible shifts in the US Federal Reserve's timeline for tapering asset purchases.\nAll three major US stock indexes lost ground, with the Nasdaq Composite Index's weighed down as rising US Treasury yields pressured market-leading growth stocks.\nThey also posted weekly losses, with the S&P index suffering its biggest two-week drop since February.\n\"The market is struggling with prospects for tighter fiscal policy due to tax increases, and tighter monetary policy due to Fed tapering,\" said David Carter, chief investment officer at Lenox Wealth Advisors in New York.\n\"Equity markets are also a little softer due to today's weak Consumer Sentiment data,\" Carter added. \"It's triggering concerns that the Delta variant could slow economic growth.\"\nA potential hike in corporate taxes could eat into earnings also weigh on markets, with leading Democrats seeking to raise the top tax rate on corporations to 26.5 per cent from the current 21 per cent.\nWhile consumer sentiment steadied this month it remains depressed, according to a University of Michigan report, as Americans postpone purchases while inflation remains high.\nInflation is likely to be a major issue next week, when the Federal Open Markets Committee holds its two-day monetary policy meeting. Market participants will be watching closely for changes in nuance which could signal a shift in the Fed's tapering timeline.\n\"It has been a week of mixed economic data and we are focused clearly on what will come out of the Fed meeting next week,\" said Bill Northey, senior investment director at US Bank Wealth Management in Helena, Montana.\nThe Dow Jones Industrial Average fell 166.44 points, or 0.48 per cent, to 34,584.88; the S&P 500 lost 40.76 points, or 0.91 per cent, at 4,432.99; and the Nasdaq Composite dropped 137.96 points, or 0.91 per cent, to 15,043.97.\nThe S&P 500 ended below its 50-day moving average, which in recent history has proven a rather sturdy support level.\nOf the 11 major sectors in the S&P 500, all but healthcare ended in the red, with materials and utilities suffering the biggest percentage drops.\nWall Street ends rollercoaster week sharply lower\nCovid-19 vaccine manufacturers Pfizer and Moderna dropped 1.3 per cent and 2.4 per cent, respectively, as US health officials moved the debate over booster doses to a panel of independent experts.\nUS Steel Corp shed 8 per cent after it unveiled a US$3 billion (S$4 billion) mini-mill investment plan.\nVolume and volatility spiked toward the end of the session due to \"triple witching,\" which is the quarterly, simultaneous expiration of stock options, stock index futures, and stock index options contracts.\nVolume on US exchanges was 15.51 billion shares, compared with the 9.70 billion average over the last 20 trading days.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.97-to-1 ratio; on Nasdaq, a 1.00-to-1 ratio favoured advancers.\nThe S&P 500 posted seven new 52-week highs and two new lows; the Nasdaq Composite recorded 67 new highs and 82 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":101,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887990789,"gmtCreate":1631953004641,"gmtModify":1676530677449,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887990789","repostId":"1171558890","repostType":4,"repost":{"id":"1171558890","pubTimestamp":1631921912,"share":"https://www.laohu8.com/m/news/1171558890?lang=&edition=full","pubTime":"2021-09-18 07:38","market":"us","language":"en","title":"US IPO Week Ahead: Software, consumer products, and payment tech lead a diverse 14 IPO week","url":"https://stock-news.laohu8.com/highlight/detail?id=1171558890","media":"renaissancecap...","summary":"Summer may be over, but the IPO market is just heating up as 14 IPOs are slated to raise $5.3 billio","content":"<p>Summer may be over, but the IPO market is just heating up as 14 IPOs are slated to raise $5.3 billion in the week ahead. The diverse group includes software, consumer products, payment technology, and more.</p>\n<p>The largest deal of the week,<b>Freshworks</b>(FRSH) plans to raise $855 million at a $9.6 billion market cap. The company’s core product is its customer support software, and it also offers IT service management software and a nascent competitor to CRM solutions. While losses are expected to increase with S&amp;M spending, Freshworks has delivered solid growth and 100%+ net dollar-based revenue retention as of 6/30/21.</p>\n<p>Canadian consumer products company&nbsp;<b>Knowlton Development</b>(KDC) plans to raise $800 million at a $3.1 billion market cap. Over the past three years, Knowlton has been responsible for co-developing 9,000+ products across a variety of categories, and its products are sold by its brand partners in 70+ countries. Despite using offering proceeds to pay down debt, Knowlton will be leveraged post-IPO.</p>\n<p>Restaurant payment processor&nbsp;<b>Toast</b>(TOST) plans to raise $685 million at a $17.9 billion market cap. Toast provides a suite of integrated payment and software solutions that are designed to streamline restaurant operations. The company grew ARR over 100% in the 1H21, though it has historically been unprofitable, and growth could slow as tailwinds from restaurants reopening abate.</p>\n<p>Global money transfer firm&nbsp;<b>Remitly Global</b>(RELY) plans to raise $487 million at a $7.5 billion market cap. Remitly provides digital financial services for immigrants and their families in over 135 countries, and it has expanded its core cross-border remittance product to over 1,700 corridors worldwide. The company has demonstrated growth and margin improvement, though it remains unprofitable.</p>\n<p>Software firm&nbsp;<b>Clearwater Analytics</b>(CWAN) plans to raise $450 million at a $3.7 billion market cap. Clearwater provides its 1,000+ clients with cloud-native software that allows them to simplify their investment accounting operations, and the company has a 100% recurring revenue model. A new investor and certain existing shareholders intend to purchase $150 million worth of shares in the IPO.</p>\n<p>Food company&nbsp;<b>Sovos Brands</b>(SOVO) plans to raise $350 million at a $1.5 billion market cap. Formed by Advent International, Sovos Brands offers a select group of acquired premium food brands. According to the company, its largest brand of products, Rao's, included the #1 selling SKU in the pasta and pizza sauce category. Profitable with solid growth, Sovos will be leveraged post-IPO.</p>\n<p>Customer engagement software provider&nbsp;<b>EngageSmart</b>(ESMT) plans to raise $349 million at a $4.1 billion market cap. The company provides software that simplifies online workflows like paperless billing, electronic payment processing, scheduling, and client communication. While growth may slow post-pandemic, EngageSmart has a sticky customer based and a long track record of profitability.</p>\n<p>Hiring solutions provider&nbsp;<b>Sterling Check</b>(STER) plans to raise $300 million at a $2.1 billion market cap. Sterling is one of the leading US providers of background checks for corporate and government customers. The company serves more than 50% of the Fortune 100, often with exclusive contracts, though it operates in a highly competitive market.</p>\n<p>Jewelry retailer&nbsp;<b>Brilliant Earth Group</b>(BRLT) plans to raise $250 million at a $1.4 billion. Brilliant Earth is a digital-first jewelry company and a global leader in ethically sourced fine jewelry. The company has sold to consumers in all US states and over 50 countries, and has served over 370,000 customers through its e-commerce platform and 13 showrooms.</p>\n<p>Online fashion platform&nbsp;<b>a.k.a. Brands</b>(AKA) plans to raise $250 million at a $2.3 billion market cap. a.k.a. acquires digitally-focused fashion brands oriented toward millennial and Gen Z consumers, starting with its acquisition of Princess Polly in 2018. The company has successfully expanded Princess Polly and has a long runway to grow its brands in the US, but its M&amp;A strategy carries execution risk.</p>\n<p>COVID-19 test maker&nbsp;<b>Cue Health</b>(HLTH) plans to raise $200 million at a $2.4 billion market cap. Cue’s first commercially available diagnostic test for use with its Cue Health Monitoring System is its COVID-19 Test Kit, which has been authorized by two EUAs. Cue has five additional Test Kits in late-stage technical development, for which it expects to begin seeking FDA authorization or clearance in the 2H22.</p>\n<p>London-listed crypto mining company&nbsp;<b>Argo Blockchain</b>(ARBK) plans to raise $138 million at an $855 million market cap. Argo states that it is a leading blockchain technology company focused on large-scale mining of Bitcoin and other cryptocurrencies. Argo has a fleet of more than 21,000 purpose-built computers (mining machines) and can generate more than 1,075 petahash per second.</p>\n<p>Personalized supplements seller&nbsp;<b>Thorne Healthtech</b>(THRN) plans to raise $126 million at an $892 million market cap. The company’s vertically integrated brands, Thorne and Onegevity, provide actionable insights and personalized data, products, and services. Profitable with strong growth, Thorne has a base of more than 3 million customers.</p>\n<p>Canadian bank&nbsp;<b>VersaBank</b>(VBNK) plans to raise $50 million at a $269 million market cap. VersaBank is a Canadian Schedule I chartered bank and states that it is one of the world's first fully digital financial institutions. As of July 31, 2021, VersaBank had $1.8 billion in assets, $1.6 billion in loans, $1.5 billion in deposits, and $202 million in stockholders' equity.</p>","source":"lsy1619493174116","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: Software, consumer products, and payment tech lead a diverse 14 IPO week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: Software, consumer products, and payment tech lead a diverse 14 IPO week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 07:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/86272/US-IPO-Week-Ahead-Software-consumer-products-and-payment-tech-lead-a-divers><strong>renaissancecap...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summer may be over, but the IPO market is just heating up as 14 IPOs are slated to raise $5.3 billion in the week ahead. The diverse group includes software, consumer products, payment technology, and...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86272/US-IPO-Week-Ahead-Software-consumer-products-and-payment-tech-lead-a-divers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HLTH":"Cue Health Inc.","BRLT":"Brilliant Earth Group, Inc.","RELY":"Remitly Global, Inc.","STER":"Sterling Check Corp.","ARBK":"Argo Blockchain Plc","FRSH":"Freshworks","SOVO":"Sovos Brands, Inc.","ESMT":"EngageSmart Inc.","THRN":"Thorne Healthtech","AKA":"a.k.a. Brands Holding Corp.","TOST":"Toast, Inc.","CWAN":"Clearwater Analytics Holdings, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86272/US-IPO-Week-Ahead-Software-consumer-products-and-payment-tech-lead-a-divers","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171558890","content_text":"Summer may be over, but the IPO market is just heating up as 14 IPOs are slated to raise $5.3 billion in the week ahead. The diverse group includes software, consumer products, payment technology, and more.\nThe largest deal of the week,Freshworks(FRSH) plans to raise $855 million at a $9.6 billion market cap. The company’s core product is its customer support software, and it also offers IT service management software and a nascent competitor to CRM solutions. While losses are expected to increase with S&M spending, Freshworks has delivered solid growth and 100%+ net dollar-based revenue retention as of 6/30/21.\nCanadian consumer products company Knowlton Development(KDC) plans to raise $800 million at a $3.1 billion market cap. Over the past three years, Knowlton has been responsible for co-developing 9,000+ products across a variety of categories, and its products are sold by its brand partners in 70+ countries. Despite using offering proceeds to pay down debt, Knowlton will be leveraged post-IPO.\nRestaurant payment processor Toast(TOST) plans to raise $685 million at a $17.9 billion market cap. Toast provides a suite of integrated payment and software solutions that are designed to streamline restaurant operations. The company grew ARR over 100% in the 1H21, though it has historically been unprofitable, and growth could slow as tailwinds from restaurants reopening abate.\nGlobal money transfer firm Remitly Global(RELY) plans to raise $487 million at a $7.5 billion market cap. Remitly provides digital financial services for immigrants and their families in over 135 countries, and it has expanded its core cross-border remittance product to over 1,700 corridors worldwide. The company has demonstrated growth and margin improvement, though it remains unprofitable.\nSoftware firm Clearwater Analytics(CWAN) plans to raise $450 million at a $3.7 billion market cap. Clearwater provides its 1,000+ clients with cloud-native software that allows them to simplify their investment accounting operations, and the company has a 100% recurring revenue model. A new investor and certain existing shareholders intend to purchase $150 million worth of shares in the IPO.\nFood company Sovos Brands(SOVO) plans to raise $350 million at a $1.5 billion market cap. Formed by Advent International, Sovos Brands offers a select group of acquired premium food brands. According to the company, its largest brand of products, Rao's, included the #1 selling SKU in the pasta and pizza sauce category. Profitable with solid growth, Sovos will be leveraged post-IPO.\nCustomer engagement software provider EngageSmart(ESMT) plans to raise $349 million at a $4.1 billion market cap. The company provides software that simplifies online workflows like paperless billing, electronic payment processing, scheduling, and client communication. While growth may slow post-pandemic, EngageSmart has a sticky customer based and a long track record of profitability.\nHiring solutions provider Sterling Check(STER) plans to raise $300 million at a $2.1 billion market cap. Sterling is one of the leading US providers of background checks for corporate and government customers. The company serves more than 50% of the Fortune 100, often with exclusive contracts, though it operates in a highly competitive market.\nJewelry retailer Brilliant Earth Group(BRLT) plans to raise $250 million at a $1.4 billion. Brilliant Earth is a digital-first jewelry company and a global leader in ethically sourced fine jewelry. The company has sold to consumers in all US states and over 50 countries, and has served over 370,000 customers through its e-commerce platform and 13 showrooms.\nOnline fashion platform a.k.a. Brands(AKA) plans to raise $250 million at a $2.3 billion market cap. a.k.a. acquires digitally-focused fashion brands oriented toward millennial and Gen Z consumers, starting with its acquisition of Princess Polly in 2018. The company has successfully expanded Princess Polly and has a long runway to grow its brands in the US, but its M&A strategy carries execution risk.\nCOVID-19 test maker Cue Health(HLTH) plans to raise $200 million at a $2.4 billion market cap. Cue’s first commercially available diagnostic test for use with its Cue Health Monitoring System is its COVID-19 Test Kit, which has been authorized by two EUAs. Cue has five additional Test Kits in late-stage technical development, for which it expects to begin seeking FDA authorization or clearance in the 2H22.\nLondon-listed crypto mining company Argo Blockchain(ARBK) plans to raise $138 million at an $855 million market cap. Argo states that it is a leading blockchain technology company focused on large-scale mining of Bitcoin and other cryptocurrencies. Argo has a fleet of more than 21,000 purpose-built computers (mining machines) and can generate more than 1,075 petahash per second.\nPersonalized supplements seller Thorne Healthtech(THRN) plans to raise $126 million at an $892 million market cap. The company’s vertically integrated brands, Thorne and Onegevity, provide actionable insights and personalized data, products, and services. Profitable with strong growth, Thorne has a base of more than 3 million customers.\nCanadian bank VersaBank(VBNK) plans to raise $50 million at a $269 million market cap. VersaBank is a Canadian Schedule I chartered bank and states that it is one of the world's first fully digital financial institutions. As of July 31, 2021, VersaBank had $1.8 billion in assets, $1.6 billion in loans, $1.5 billion in deposits, and $202 million in stockholders' equity.","news_type":1},"isVote":1,"tweetType":1,"viewCount":64,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887907745,"gmtCreate":1631952934887,"gmtModify":1676530677422,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>$$$$$","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>$$$$$","text":"$NIO Inc.(NIO)$$$$$$","images":[{"img":"https://static.tigerbbs.com/f411e551e02b25dab0f07f3d8dfe4e86","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887907745","isVote":1,"tweetType":1,"viewCount":18,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":884137913,"gmtCreate":1631866319832,"gmtModify":1676530656372,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>$$$$","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>$$$$","text":"$NIO Inc.(NIO)$$$$$","images":[{"img":"https://static.tigerbbs.com/981ce6b2bd2989f2a8965b0a6f4bcd32","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/884137913","isVote":1,"tweetType":1,"viewCount":16,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":885870802,"gmtCreate":1631780163806,"gmtModify":1676530633870,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885870802","repostId":"1132753188","repostType":4,"repost":{"id":"1132753188","pubTimestamp":1631778496,"share":"https://www.laohu8.com/m/news/1132753188?lang=&edition=full","pubTime":"2021-09-16 15:48","market":"us","language":"en","title":"Amazon's New TVs Are No Threat to Roku","url":"https://stock-news.laohu8.com/highlight/detail?id=1132753188","media":"Motley Fool","summary":"Two analysts argue that Roku will cope just fine with Amazon's new line of Fire TV devices.","content":"<p><b>Key Points</b></p>\n<ul>\n <li>A pair of analysts issued updated analyst notes defending Roku's market leadership following the announcement of Amazon's new line of Fire TV devices.</li>\n <li>Pricing is aggressive, but not as promotional as many had feared. The growing number of TV manufacturers putting out Roku OS-powered smart HDTVs will be just fine.</li>\n <li>The TV is overrated, as much cheaper sticks and dongles are the ultimate gateway to a streaming operating system.</li>\n</ul>\n<p>A cruel summer for&nbsp;<b>Roku</b>(NASDAQ:ROKU)&nbsp;investors seemed to get worse last week when&nbsp;<b>Amazon.com</b>(NASDAQ:AMZN)&nbsp;introduced a new line</p>\n<p>Roku stock has been retreating on the news, and it's easy to see why at first. Amazon is a monster that isn't afraid to subsidize hardware to gain new users. \"Your margin is my opportunity,\" is one of Amazon founder and former CEO Jeff Bezos' most enduring quotes.</p>\n<p>However, a couple of analysts did step up after the Amazon announcement to back up Roku's market position. It may seem like a normal defense mechanism for Roku-bullish Wall Street pros to come to the streaming media pioneer's side, but their arguments do make sense.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d2c4537c87920ef2e9f4eb487ed39323\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>Going for the power button on the Roku remote control</b></p>\n<p>Making lemonade out of lemons, KeyBanc analyst Justin Patterson claims that Amazon's announcement slides in as an \"incremental positive\" to Roku's competitive position. He doesn't see any material differences between the specs on the new Fire TV devices and what Roku is already offering. He also feels that the third-party manufacturers of smart TVs with Roku's operating system preinstalled match up well on the pricing that Amazon introduced last week. Consumers aren't likely to perceive a need to go with a Fire TV flat-screen, so the rollout won't change the already competitive landscape where Roku is faring so well.</p>\n<p>Nicholas Zangler at Stephens agrees. Fears that Amazon was going to price its smart TVs below cost in an effort to increase the audience for its ecosystem failed to materialize. Amazon may very well have some ridiculous Black Friday and Cyber Monday deals on these sets come late November, but the entire industry is promotional that time of year anyway.</p>\n<p>Roku OS is installed in 38% of the smart TVs shipped in the U.S. market, and that's not likely to change just because Amazon is now making TVs. If anything, Amazon actually making HDTVs may make some of its partners think twice about supporting Fire TV. A big draw for Roku -- for TV manufacturers, streaming service providers, and ultimately consumers -- is its agnosticism. Roku plays nice with thousands of popular apps, and it will continue to be the partner of choice for TV makers, platform operators, and families perched on living room couches.</p>\n<p>We also shouldn't put too much weight on the TV itself. I own a pair of Fire TV HDTVs. They both have Roku dongles in their HDMI ports to fuel my streaming experience. The dongle is the key. These plug-in devices that start as low as $20 are cheap enough to be replaced as needed. They also offer the portability that a TV does not. If you travel, you will quickly embrace the stick over the built-in operating system of a TV.</p>\n<p>Folks also aren't necessarily in the market for a new TV. A TV -- even a smart one -- should last for several years before it needs to be upgraded. A new dongle at less than 10% of the cost of a new set does the trick in most cases.</p>\n<p>It's obvious why Amazon wants Fire TV to be a bigger force here. Roku's&nbsp;55.1 million active users&nbsp;are averaging more than three hours a day of streaming. Marketers also crave ways to reach a streaming audience that spends much of that time on commercial-free services. Ad revenue per user has soared 46% for Roku over the past year, and it will continue to climb as connected TV advertising grows as a chunk of marketing campaign budgets. However, Amazon's just putting out a TV isn't going to unseat Roku from leadership within the ranks of&nbsp;streaming service stocks. If all Amazon does with its new TVs is draw attention to the digital migration process, it could be a win for all the industry players.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon's New TVs Are No Threat to Roku</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon's New TVs Are No Threat to Roku\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-16 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/15/amazons-new-tvs-are-no-threat-to-roku/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nA pair of analysts issued updated analyst notes defending Roku's market leadership following the announcement of Amazon's new line of Fire TV devices.\nPricing is aggressive, but not as ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/15/amazons-new-tvs-are-no-threat-to-roku/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ROKU":"Roku Inc"},"source_url":"https://www.fool.com/investing/2021/09/15/amazons-new-tvs-are-no-threat-to-roku/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132753188","content_text":"Key Points\n\nA pair of analysts issued updated analyst notes defending Roku's market leadership following the announcement of Amazon's new line of Fire TV devices.\nPricing is aggressive, but not as promotional as many had feared. The growing number of TV manufacturers putting out Roku OS-powered smart HDTVs will be just fine.\nThe TV is overrated, as much cheaper sticks and dongles are the ultimate gateway to a streaming operating system.\n\nA cruel summer for Roku(NASDAQ:ROKU) investors seemed to get worse last week when Amazon.com(NASDAQ:AMZN) introduced a new line\nRoku stock has been retreating on the news, and it's easy to see why at first. Amazon is a monster that isn't afraid to subsidize hardware to gain new users. \"Your margin is my opportunity,\" is one of Amazon founder and former CEO Jeff Bezos' most enduring quotes.\nHowever, a couple of analysts did step up after the Amazon announcement to back up Roku's market position. It may seem like a normal defense mechanism for Roku-bullish Wall Street pros to come to the streaming media pioneer's side, but their arguments do make sense.\nIMAGE SOURCE: GETTY IMAGES.\nGoing for the power button on the Roku remote control\nMaking lemonade out of lemons, KeyBanc analyst Justin Patterson claims that Amazon's announcement slides in as an \"incremental positive\" to Roku's competitive position. He doesn't see any material differences between the specs on the new Fire TV devices and what Roku is already offering. He also feels that the third-party manufacturers of smart TVs with Roku's operating system preinstalled match up well on the pricing that Amazon introduced last week. Consumers aren't likely to perceive a need to go with a Fire TV flat-screen, so the rollout won't change the already competitive landscape where Roku is faring so well.\nNicholas Zangler at Stephens agrees. Fears that Amazon was going to price its smart TVs below cost in an effort to increase the audience for its ecosystem failed to materialize. Amazon may very well have some ridiculous Black Friday and Cyber Monday deals on these sets come late November, but the entire industry is promotional that time of year anyway.\nRoku OS is installed in 38% of the smart TVs shipped in the U.S. market, and that's not likely to change just because Amazon is now making TVs. If anything, Amazon actually making HDTVs may make some of its partners think twice about supporting Fire TV. A big draw for Roku -- for TV manufacturers, streaming service providers, and ultimately consumers -- is its agnosticism. Roku plays nice with thousands of popular apps, and it will continue to be the partner of choice for TV makers, platform operators, and families perched on living room couches.\nWe also shouldn't put too much weight on the TV itself. I own a pair of Fire TV HDTVs. They both have Roku dongles in their HDMI ports to fuel my streaming experience. The dongle is the key. These plug-in devices that start as low as $20 are cheap enough to be replaced as needed. They also offer the portability that a TV does not. If you travel, you will quickly embrace the stick over the built-in operating system of a TV.\nFolks also aren't necessarily in the market for a new TV. A TV -- even a smart one -- should last for several years before it needs to be upgraded. A new dongle at less than 10% of the cost of a new set does the trick in most cases.\nIt's obvious why Amazon wants Fire TV to be a bigger force here. Roku's 55.1 million active users are averaging more than three hours a day of streaming. Marketers also crave ways to reach a streaming audience that spends much of that time on commercial-free services. Ad revenue per user has soared 46% for Roku over the past year, and it will continue to climb as connected TV advertising grows as a chunk of marketing campaign budgets. However, Amazon's just putting out a TV isn't going to unseat Roku from leadership within the ranks of streaming service stocks. If all Amazon does with its new TVs is draw attention to the digital migration process, it could be a win for all the industry players.","news_type":1},"isVote":1,"tweetType":1,"viewCount":125,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885870973,"gmtCreate":1631780153592,"gmtModify":1676530633870,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885870973","repostId":"1170247041","repostType":4,"repost":{"id":"1170247041","pubTimestamp":1631778665,"share":"https://www.laohu8.com/m/news/1170247041?lang=&edition=full","pubTime":"2021-09-16 15:51","market":"us","language":"en","title":"Adobe challenges Shopify, adds PayPal payment services to e-commerce platform","url":"https://stock-news.laohu8.com/highlight/detail?id=1170247041","media":"seekingalpha","summary":"Adobe (ADBE+2.5%) willadd payment services powered by the PayPal Commerce Platform (PYPL+0.2%) to it","content":"<ul>\n <li>Adobe (ADBE+2.5%) willadd payment services&nbsp;powered by the PayPal Commerce Platform (PYPL+0.2%) to its merchant e-commerce platform Adobe Commerce. Previously, Adobe merchants had to find their own payment systems but payment methods will be fully&nbsp;integrated by the end of this year and sellers will be able to easily accept credit and debit cards, PayPal and Venmo payments from customers through the system.</li>\n <li>\"What they're really looking for is simplicity of operations and having all of their reporting and reconciliation in a single tool set,\" Adobe's Senior Director of Commerce Strategy Peter&nbsp;Sheldon told&nbsp;Reuters.</li>\n <li>The move brings Adobe in direct competition with Shopify (SHOP+1.0%), which brought in over two-thirds of its 2020 revenue from its merchant services segment.</li>\n <li>Adobe plans to expand payment services to Canada, Western Europe, and Australia by 2022 and says that it is not tied down to only processing payments with PayPal.</li>\n <li>Adobe will release its Q3 2021 results on September 21after the market closes.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adobe challenges Shopify, adds PayPal payment services to e-commerce platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdobe challenges Shopify, adds PayPal payment services to e-commerce platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-16 15:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3740085-adobe-challenges-shopify-adds-payment-services-to-e-commerce-platform><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Adobe (ADBE+2.5%) willadd payment services powered by the PayPal Commerce Platform (PYPL+0.2%) to its merchant e-commerce platform Adobe Commerce. Previously, Adobe merchants had to find their own ...</p>\n\n<a href=\"https://seekingalpha.com/news/3740085-adobe-challenges-shopify-adds-payment-services-to-e-commerce-platform\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SHOP":"Shopify Inc","PYPL":"PayPal","ADBE":"Adobe"},"source_url":"https://seekingalpha.com/news/3740085-adobe-challenges-shopify-adds-payment-services-to-e-commerce-platform","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1170247041","content_text":"Adobe (ADBE+2.5%) willadd payment services powered by the PayPal Commerce Platform (PYPL+0.2%) to its merchant e-commerce platform Adobe Commerce. Previously, Adobe merchants had to find their own payment systems but payment methods will be fully integrated by the end of this year and sellers will be able to easily accept credit and debit cards, PayPal and Venmo payments from customers through the system.\n\"What they're really looking for is simplicity of operations and having all of their reporting and reconciliation in a single tool set,\" Adobe's Senior Director of Commerce Strategy Peter Sheldon told Reuters.\nThe move brings Adobe in direct competition with Shopify (SHOP+1.0%), which brought in over two-thirds of its 2020 revenue from its merchant services segment.\nAdobe plans to expand payment services to Canada, Western Europe, and Australia by 2022 and says that it is not tied down to only processing payments with PayPal.\nAdobe will release its Q3 2021 results on September 21after the market closes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":143,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885847143,"gmtCreate":1631780111382,"gmtModify":1676530633853,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/885847143","repostId":"1173337731","repostType":4,"isVote":1,"tweetType":1,"viewCount":90,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":887999173,"gmtCreate":1631953026592,"gmtModify":1676530677457,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/887999173","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","pubTimestamp":1631950800,"share":"https://www.laohu8.com/m/news/2168957763?lang=&edition=full","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research &amp; Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication &amp; Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803596877,"gmtCreate":1627446220599,"gmtModify":1703490136416,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like&nbsp;my comment pls&nbsp;","listText":"Like&nbsp;my comment pls&nbsp;","text":"Like my comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/803596877","repostId":"2154003945","repostType":4,"isVote":1,"tweetType":1,"viewCount":66,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887999218,"gmtCreate":1631953055334,"gmtModify":1676530677465,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/887999218","repostId":"1128389145","repostType":4,"repost":{"id":"1128389145","pubTimestamp":1631933002,"share":"https://www.laohu8.com/m/news/1128389145?lang=&edition=full","pubTime":"2021-09-18 10:43","market":"us","language":"en","title":"Lucid Motors Price Predictions: Can LCID Stock Really Reach $30?","url":"https://stock-news.laohu8.com/highlight/detail?id=1128389145","media":"investorplace","summary":"Lucid Motors(NASDAQ:LCID) is having a booming day as it continues to rebound from an early September","content":"<p><b>Lucid Motors</b>(NASDAQ:<b><u>LCID</u></b>) is having a booming day as it continues to rebound from an early September slump. The stock is moving upwards after receiving an attractive rating from Bank of America. With institutional investors on its side once again, and a new EPA rating, investors stand to wonder where LCID stock will go. Hence, Lucid Motors price predictions are in high demand.</p>\n<p>It’s inarguable that Lucid is rallying in hopes of becoming the next&nbsp;<b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>). But Tesla is vastly more storied, has more experience getting cars on the road, and it has a superstar CEO with massive ambitions for the market. However, that’s not to say it has perfect vehicles. The cars themselves are the most important part, and with Lucid’s newest EPA rating, it’s putting Tesla in the hot seat.</p>\n<p>As the company announced yesterday, the Environmental Protection Agency&nbsp;awarded the Lucid Air Dream Edition Range with a 520-mile range. That’s by far the longest range for an electric vehicle on a single charge. For reference, Tesla’s longest-range vehicle&nbsp;only offers about 412 mileson a single charge. Lucid is creating an obvious edge for itself.</p>\n<p>Lucid Motors Price Predictions Surge on Bank of America Rating</p>\n<p>Following this announcement, LCID stock is getting the benefit of a new Bank of America note. The analyst calls the brand a “combination of Ferrari and Tesla,” and is putting a hefty rating on LCID stock. The bullish price point of $30 is in and of itself inciting buying interest. In the early hours of today’s session, trading volume of LCID is over 40 million shares. Shares are increasing 10% on the news.</p>\n<p>What do analysts at large think of LCID stock? Is it built to last? Is $30 much too optimistic? Let’s take a look at some&nbsp;Lucid Motors price predictionsto get an idea of broader sentiment:</p>\n<ul>\n <li>Of course, bringing in all of the news today is John Murphy’s price target out of Bank of America. Murphy gives the stock a strong “buy” rating and a $30 price target.</li>\n <li>Also bullish on LCID is Itay Michaeli, an analyst at Citigroup. Michaeli targets a price of $28 for LCID.</li>\n <li>Adam Jonas is a known bear on LCID stock. The Morgan Stanley analyst is has a “sell” rating on LCID, anticipating a drop in price down to $12.</li>\n</ul>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lucid Motors Price Predictions: Can LCID Stock Really Reach $30?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLucid Motors Price Predictions: Can LCID Stock Really Reach $30?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 10:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/lucid-motors-price-predictions-can-lcid-stock-really-reach-30/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Lucid Motors(NASDAQ:LCID) is having a booming day as it continues to rebound from an early September slump. The stock is moving upwards after receiving an attractive rating from Bank of America. With ...</p>\n\n<a href=\"https://investorplace.com/2021/09/lucid-motors-price-predictions-can-lcid-stock-really-reach-30/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc"},"source_url":"https://investorplace.com/2021/09/lucid-motors-price-predictions-can-lcid-stock-really-reach-30/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128389145","content_text":"Lucid Motors(NASDAQ:LCID) is having a booming day as it continues to rebound from an early September slump. The stock is moving upwards after receiving an attractive rating from Bank of America. With institutional investors on its side once again, and a new EPA rating, investors stand to wonder where LCID stock will go. Hence, Lucid Motors price predictions are in high demand.\nIt’s inarguable that Lucid is rallying in hopes of becoming the next Tesla(NASDAQ:TSLA). But Tesla is vastly more storied, has more experience getting cars on the road, and it has a superstar CEO with massive ambitions for the market. However, that’s not to say it has perfect vehicles. The cars themselves are the most important part, and with Lucid’s newest EPA rating, it’s putting Tesla in the hot seat.\nAs the company announced yesterday, the Environmental Protection Agency awarded the Lucid Air Dream Edition Range with a 520-mile range. That’s by far the longest range for an electric vehicle on a single charge. For reference, Tesla’s longest-range vehicle only offers about 412 mileson a single charge. Lucid is creating an obvious edge for itself.\nLucid Motors Price Predictions Surge on Bank of America Rating\nFollowing this announcement, LCID stock is getting the benefit of a new Bank of America note. The analyst calls the brand a “combination of Ferrari and Tesla,” and is putting a hefty rating on LCID stock. The bullish price point of $30 is in and of itself inciting buying interest. In the early hours of today’s session, trading volume of LCID is over 40 million shares. Shares are increasing 10% on the news.\nWhat do analysts at large think of LCID stock? Is it built to last? Is $30 much too optimistic? Let’s take a look at some Lucid Motors price predictionsto get an idea of broader sentiment:\n\nOf course, bringing in all of the news today is John Murphy’s price target out of Bank of America. Murphy gives the stock a strong “buy” rating and a $30 price target.\nAlso bullish on LCID is Itay Michaeli, an analyst at Citigroup. Michaeli targets a price of $28 for LCID.\nAdam Jonas is a known bear on LCID stock. The Morgan Stanley analyst is has a “sell” rating on LCID, anticipating a drop in price down to $12.","news_type":1},"isVote":1,"tweetType":1,"viewCount":25,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886565212,"gmtCreate":1631606795836,"gmtModify":1676530588284,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/886565212","repostId":"2167582155","repostType":4,"repost":{"id":"2167582155","pubTimestamp":1631605809,"share":"https://www.laohu8.com/m/news/2167582155?lang=&edition=full","pubTime":"2021-09-14 15:50","market":"us","language":"en","title":"These 2 High-Growth Stocks Could Help Power the Bull Market's Next Record Run","url":"https://stock-news.laohu8.com/highlight/detail?id=2167582155","media":"Motley Fool","summary":"You might think that neither of these companies is an obvious pick to be a big winner when growth gets rolling again -- but look closer.","content":"<p>Every market surge has its leaders and laggards. Sometimes, the coming winners are relatively easy to spot, but in other cases, their strengths only become clear to everyone with the benefit of hindsight.</p>\n<p>I feel that <b>Roku</b> (NASDAQ:ROKU) and <b>Sleep Number</b> (NASDAQ:SNBR) -- yes, Sleep Number -- could be among the stocks that power the next bull market. Here's why.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c9117b8a76bcb5de90b5339d7fcf0fff\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Roku</h2>\n<p>Roku stock is not a particularly popular bet on Wall Street these days. Some traders see it as an earlier-stage pandemic play that will flounder now that we're once again spending more time outside of our homes and less time streaming escapism. Last week, <b>Amazon.com</b> (NASDAQ:AMZN) rolled out a new line of Fire TV HDTVs, including the first-ever Amazon-built television.</p>\n<p>Let's tackle the Amazon challenge first. The new sets pack impressive specs at even more impressive prices. They start as low as $370 for an Alexa-fueled experience that feeds right into the Amazon Fire TV ecosystem. But will they become popular enough to dethrone Roku?</p>\n<p>Flat screens with built-in smart TV hardware and software platforms are popular, and Roku currently commands 38% of that market. However, for most consumers, the solution often comes down to just buying a $20 or $30 dongle -- cheap tech that a person can take with them wherever they travel, and that will also outlive the obsolescence of whatever gargantuan HDTV they own.</p>\n<p>Roku has been competing with Amazon's cutthroat pricing for the past seven years. And it has steadily found ways to compete with challengers that include three of the world's most valuable tech titans.</p>\n<p>There are now 55.1 million active users who rely on Roku to feed their streaming habits -- to the tune of more than three hours of viewing a day, on average. Roku's audience has grown by 28% over the past year, and average revenue per user rose by 46% as marketers paid up to reach Roku's engaged audience.</p>\n<p>One should never underestimate the power of a hungry Amazon, but Roku will continue to be the bar-raising leader. It's the obvious pick for consumers coveting its service agnosticism and its thousands of available apps. Its recent push into original content is just the cherry on top for the undisputed champ of streaming service stocks.</p>\n<p>Are we spending more time outside now? Sure! Will you still come back to watch the perpetually widening options of great must-see TV? Absolutely. Why do you think Amazon is making its own TVs now?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7e6560ed09faeaf46257ea7d4203d0b2\" tg-width=\"700\" tg-height=\"393\" width=\"100%\" height=\"auto\"><span>Image source: Sleep Number.</span></p>\n<h2>Sleep Number</h2>\n<p>Some people put their money under their mattress, but smart investors may want to consider investing some of their money <i>in</i> the mattress. Sleep Number makes air-chambered mattresses with easily adjustable firmness based on a sleeper's desires.</p>\n<p>Sleep Number has always stood out within a challenging mattress market thanks to its differentiated product, and it stands out even more now that it has debuted its Sleep Number 360 bed. Billed as the company's first smart bed, it monitors people's sleep levels and adjusts for them throughout the night. From firmness, heat or cooling, and even elevation levels, Sleep Number provides a customized experience with tech that none of its peers can offer.</p>\n<p>Customers love it. Sleep Number sales soared by 70% in its latest quarter. A lot of companies have been cranking out ridiculous year-over-year growth numbers lately because the early stage of the pandemic -- 2020's second quarter -- was so challenging. But even measured against the more normal climate that prevailed in Q2 2019, Sleep Number's top line was up by 36% -- and its bottom line is growing even faster.</p>\n<p>Investors weren't impressed by Sleep Number's latest report. It was actually a rare miss on the bottom line, and management had warned that supply chain constraints would drag on its operations in June and July. Thankfully, these are all transitory troubles. We've been spending a lot more time at home over the past two years, and putting extra wear and tear on our beds. When it comes time to upgrade your mattress -- and you may be due about now -- don't be surprised if Sleep Number winds up being your first choice. Will that make Sleep Number a growth stock to own for the next bull market? Sleep on it.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 2 High-Growth Stocks Could Help Power the Bull Market's Next Record Run</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 2 High-Growth Stocks Could Help Power the Bull Market's Next Record Run\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-14 15:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/13/2-high-growth-stocks-could-help-power-bull-markets/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Every market surge has its leaders and laggards. Sometimes, the coming winners are relatively easy to spot, but in other cases, their strengths only become clear to everyone with the benefit of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/13/2-high-growth-stocks-could-help-power-bull-markets/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNBR":"Sleep Number Corporation","ROKU":"Roku Inc"},"source_url":"https://www.fool.com/investing/2021/09/13/2-high-growth-stocks-could-help-power-bull-markets/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167582155","content_text":"Every market surge has its leaders and laggards. Sometimes, the coming winners are relatively easy to spot, but in other cases, their strengths only become clear to everyone with the benefit of hindsight.\nI feel that Roku (NASDAQ:ROKU) and Sleep Number (NASDAQ:SNBR) -- yes, Sleep Number -- could be among the stocks that power the next bull market. Here's why.\nImage source: Getty Images.\nRoku\nRoku stock is not a particularly popular bet on Wall Street these days. Some traders see it as an earlier-stage pandemic play that will flounder now that we're once again spending more time outside of our homes and less time streaming escapism. Last week, Amazon.com (NASDAQ:AMZN) rolled out a new line of Fire TV HDTVs, including the first-ever Amazon-built television.\nLet's tackle the Amazon challenge first. The new sets pack impressive specs at even more impressive prices. They start as low as $370 for an Alexa-fueled experience that feeds right into the Amazon Fire TV ecosystem. But will they become popular enough to dethrone Roku?\nFlat screens with built-in smart TV hardware and software platforms are popular, and Roku currently commands 38% of that market. However, for most consumers, the solution often comes down to just buying a $20 or $30 dongle -- cheap tech that a person can take with them wherever they travel, and that will also outlive the obsolescence of whatever gargantuan HDTV they own.\nRoku has been competing with Amazon's cutthroat pricing for the past seven years. And it has steadily found ways to compete with challengers that include three of the world's most valuable tech titans.\nThere are now 55.1 million active users who rely on Roku to feed their streaming habits -- to the tune of more than three hours of viewing a day, on average. Roku's audience has grown by 28% over the past year, and average revenue per user rose by 46% as marketers paid up to reach Roku's engaged audience.\nOne should never underestimate the power of a hungry Amazon, but Roku will continue to be the bar-raising leader. It's the obvious pick for consumers coveting its service agnosticism and its thousands of available apps. Its recent push into original content is just the cherry on top for the undisputed champ of streaming service stocks.\nAre we spending more time outside now? Sure! Will you still come back to watch the perpetually widening options of great must-see TV? Absolutely. Why do you think Amazon is making its own TVs now?\nImage source: Sleep Number.\nSleep Number\nSome people put their money under their mattress, but smart investors may want to consider investing some of their money in the mattress. Sleep Number makes air-chambered mattresses with easily adjustable firmness based on a sleeper's desires.\nSleep Number has always stood out within a challenging mattress market thanks to its differentiated product, and it stands out even more now that it has debuted its Sleep Number 360 bed. Billed as the company's first smart bed, it monitors people's sleep levels and adjusts for them throughout the night. From firmness, heat or cooling, and even elevation levels, Sleep Number provides a customized experience with tech that none of its peers can offer.\nCustomers love it. Sleep Number sales soared by 70% in its latest quarter. A lot of companies have been cranking out ridiculous year-over-year growth numbers lately because the early stage of the pandemic -- 2020's second quarter -- was so challenging. But even measured against the more normal climate that prevailed in Q2 2019, Sleep Number's top line was up by 36% -- and its bottom line is growing even faster.\nInvestors weren't impressed by Sleep Number's latest report. It was actually a rare miss on the bottom line, and management had warned that supply chain constraints would drag on its operations in June and July. Thankfully, these are all transitory troubles. We've been spending a lot more time at home over the past two years, and putting extra wear and tear on our beds. When it comes time to upgrade your mattress -- and you may be due about now -- don't be surprised if Sleep Number winds up being your first choice. Will that make Sleep Number a growth stock to own for the next bull market? Sleep on it.","news_type":1},"isVote":1,"tweetType":1,"viewCount":48,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883595415,"gmtCreate":1631252186237,"gmtModify":1676530509489,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/883595415","repostId":"2166345008","repostType":4,"repost":{"id":"2166345008","pubTimestamp":1631245597,"share":"https://www.laohu8.com/m/news/2166345008?lang=&edition=full","pubTime":"2021-09-10 11:46","market":"us","language":"en","title":"3 Effective Strategies for Finding Value in Any Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2166345008","media":"Motley Fool","summary":"Whether the market is hot or not, these are some ways you can find good stocks to buy.","content":"<p>Are you struggling to find quality stocks to buy right now? With the market at around all-time highs, it isn't easy to find good investment options. The danger of buying shares of a soaring stock is that it could be at or near its peak. And if that happens, your return on the investment can be limited -- or negative -- even if the underlying business isn't bad.</p>\n<p>Below, I'll cover three effective strategies I've used to identify stocks that are potentially undervalued. Whether the market is red hot or struggling, they can be effective in either scenario.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f94e1247acad42c21ee75869932e8f10\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>1. Finding large gaps between trailing and forward earnings multiples</h2>\n<p>The price-to-earnings (P/E) ratio is a useful multiple that you can use to compare stocks. The problem is that even <a href=\"https://laohu8.com/S/AONE.U\">one</a> bad quarter can negatively impact this number. Whether it's a big acquisition or the coronavirus pandemic, a company's results can look significantly worse than they otherwise should. One way to find this type of discrepancy is by comparing the trailing P/E, which looks at a company's earnings over the past 12 months vs. its <i>forward&nbsp;</i>P/E, which factors in the earnings that analysts expect from the business over the next year.</p>\n<p>A stock that trades at a high trailing P/E but a low forward P/E is one that could be undervalued. With soft earnings numbers, its trailing P/E won't look so great. One stock that you can find using this approach is&nbsp;healthcare company&nbsp;<b>Merck</b> (NYSE:MRK). The stock's trailing P/E is over 35 but its forward P/E is less than 15. The drugmaker's revenue of $48 billion in 2020 was up just 2.4% from the previous year and net income of $7.1 billion declined by 28%.</p>\n<p>Management says that without the negative impacts of the pandemic (people have been forgoing regular care amid COVID-19 and even cancer diagnoses declined significantly last year), the growth rate for the top line would have been closer to 9%. Now, with vaccination rates increasing, there's hope that COVID-19 will be less of a disruptor in the future for the healthcare industry. And that's why Merck could be an intriguing option right now and a strong recovery play. In addition, with the recent spinoff of <b>Organon</b>, which focuses on women's health, Merck expects to benefit from operating efficiencies of $500 million this year and $1.5 billion in total over the next three years.</p>\n<p>Merck is an example of a company that may look overvalued right now but could be a much better buy over the next 12 months.</p>\n<h2>2. Using the Relative Strength Index to find oversold stocks</h2>\n<p>One technical indicator I use to find value is the Relative Strength Index (RSI). It looks at a stock's price movement (typically over the past 14 days) and compares its losses and gains over that time. As the losses significantly outweigh the gains, the number gets smaller. On a 0-100 scale, once it falls below 30, a stock is considered to be oversold. It is a momentum indicator that can be useful because it can identify a situation where investors have been overly bearish on a stock of late. It doesn't mean that every stock will turn around, but for pre-vetted companies on your watch list that fall into oversold territory, it can be a sign that now might be a good time to buy.</p>\n<p>Using this criteria, you can find a solid growth stock like beverage giant <b>The Boston Beer Company&nbsp;</b>(NYSE:SAM), which has fallen sharply since the release of second-quarter results in July when its numbers fell short of analyst expectations. The growth in its hard seltzer segment simply wasn't as strong as it was in the past, and investors may have been overreacting to what still is a promising investment. A number of analysts see the stock rising over 70% within the next two years.</p>\n<p>RSI isn't a surefire way to find a winning stock; some companies fall in value sharply for valid reasons and their businesses could be in trouble. But if you've already reviewed a company and know it is a quality investment, using RSI can be a way to help zero in on the right time to buy it as oftentimes negative press can weigh a stock down more than it should. For investors who can look past that, it may create an attractive buying opportunity.</p>\n<h2>3. Buying on bad news</h2>\n<p>Investing in a company that has been receiving negative press -- and is down as a result -- is another way you can find some value. It may end up leading to a stock that falls into oversold territory, but it's not always a steep enough decline to get there. Here again, context is important. If the negative press involves the company's core business and its outlook for the future, that could very well be a problem. But if the prospects for the business remain strong, it can be worth buying amid the controversy.</p>\n<p>One example here is <b>Trulieve Cannabis</b>, which is down sharply from its 52-week high. The maker of cannabis products has been struggling of late not because of poor results or even anything the business is doing wrong. Rather, shares have been tanking because the husband of the company's CEO was convicted on multiple charges. Even though there's no reason at this point to suggest Trulieve is in any trouble, the stock has still felt the effects of the negative press. For a cannabis company that is a major player in the growing marijuana industry, now could be a prime time to consider buying shares of the business.</p>\n<p>Bad news can appear concerning over the short term but a distant memory years later. In 2018, when a privacy scandal involving social media company <b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b> and consulting firm Cambridge Analytica came out, investors could have bought shares of Facebook for around $150 in the days and weeks following the news. Today, the stock trades at more than double that price.</p>\n<p>The next time you see a negative headline on the news involving a business, consider whether it will impact its long-term growth prospects and ability to generate a profit. If it doesn't and the stock is down heavily because of the press, that could be a sign that it may be worth taking a contrarian stance on it and buying shares even as it falls in value. It may be a tough decision, but it's one that can pay off later.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Effective Strategies for Finding Value in Any Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Effective Strategies for Finding Value in Any Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/3-effective-strategies-for-finding-value-in-any-ma/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Are you struggling to find quality stocks to buy right now? With the market at around all-time highs, it isn't easy to find good investment options. The danger of buying shares of a soaring stock is ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/3-effective-strategies-for-finding-value-in-any-ma/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.fool.com/investing/2021/09/09/3-effective-strategies-for-finding-value-in-any-ma/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166345008","content_text":"Are you struggling to find quality stocks to buy right now? With the market at around all-time highs, it isn't easy to find good investment options. The danger of buying shares of a soaring stock is that it could be at or near its peak. And if that happens, your return on the investment can be limited -- or negative -- even if the underlying business isn't bad.\nBelow, I'll cover three effective strategies I've used to identify stocks that are potentially undervalued. Whether the market is red hot or struggling, they can be effective in either scenario.\nImage source: Getty Images.\n1. Finding large gaps between trailing and forward earnings multiples\nThe price-to-earnings (P/E) ratio is a useful multiple that you can use to compare stocks. The problem is that even one bad quarter can negatively impact this number. Whether it's a big acquisition or the coronavirus pandemic, a company's results can look significantly worse than they otherwise should. One way to find this type of discrepancy is by comparing the trailing P/E, which looks at a company's earnings over the past 12 months vs. its forward P/E, which factors in the earnings that analysts expect from the business over the next year.\nA stock that trades at a high trailing P/E but a low forward P/E is one that could be undervalued. With soft earnings numbers, its trailing P/E won't look so great. One stock that you can find using this approach is healthcare company Merck (NYSE:MRK). The stock's trailing P/E is over 35 but its forward P/E is less than 15. The drugmaker's revenue of $48 billion in 2020 was up just 2.4% from the previous year and net income of $7.1 billion declined by 28%.\nManagement says that without the negative impacts of the pandemic (people have been forgoing regular care amid COVID-19 and even cancer diagnoses declined significantly last year), the growth rate for the top line would have been closer to 9%. Now, with vaccination rates increasing, there's hope that COVID-19 will be less of a disruptor in the future for the healthcare industry. And that's why Merck could be an intriguing option right now and a strong recovery play. In addition, with the recent spinoff of Organon, which focuses on women's health, Merck expects to benefit from operating efficiencies of $500 million this year and $1.5 billion in total over the next three years.\nMerck is an example of a company that may look overvalued right now but could be a much better buy over the next 12 months.\n2. Using the Relative Strength Index to find oversold stocks\nOne technical indicator I use to find value is the Relative Strength Index (RSI). It looks at a stock's price movement (typically over the past 14 days) and compares its losses and gains over that time. As the losses significantly outweigh the gains, the number gets smaller. On a 0-100 scale, once it falls below 30, a stock is considered to be oversold. It is a momentum indicator that can be useful because it can identify a situation where investors have been overly bearish on a stock of late. It doesn't mean that every stock will turn around, but for pre-vetted companies on your watch list that fall into oversold territory, it can be a sign that now might be a good time to buy.\nUsing this criteria, you can find a solid growth stock like beverage giant The Boston Beer Company (NYSE:SAM), which has fallen sharply since the release of second-quarter results in July when its numbers fell short of analyst expectations. The growth in its hard seltzer segment simply wasn't as strong as it was in the past, and investors may have been overreacting to what still is a promising investment. A number of analysts see the stock rising over 70% within the next two years.\nRSI isn't a surefire way to find a winning stock; some companies fall in value sharply for valid reasons and their businesses could be in trouble. But if you've already reviewed a company and know it is a quality investment, using RSI can be a way to help zero in on the right time to buy it as oftentimes negative press can weigh a stock down more than it should. For investors who can look past that, it may create an attractive buying opportunity.\n3. Buying on bad news\nInvesting in a company that has been receiving negative press -- and is down as a result -- is another way you can find some value. It may end up leading to a stock that falls into oversold territory, but it's not always a steep enough decline to get there. Here again, context is important. If the negative press involves the company's core business and its outlook for the future, that could very well be a problem. But if the prospects for the business remain strong, it can be worth buying amid the controversy.\nOne example here is Trulieve Cannabis, which is down sharply from its 52-week high. The maker of cannabis products has been struggling of late not because of poor results or even anything the business is doing wrong. Rather, shares have been tanking because the husband of the company's CEO was convicted on multiple charges. Even though there's no reason at this point to suggest Trulieve is in any trouble, the stock has still felt the effects of the negative press. For a cannabis company that is a major player in the growing marijuana industry, now could be a prime time to consider buying shares of the business.\nBad news can appear concerning over the short term but a distant memory years later. In 2018, when a privacy scandal involving social media company Facebook and consulting firm Cambridge Analytica came out, investors could have bought shares of Facebook for around $150 in the days and weeks following the news. Today, the stock trades at more than double that price.\nThe next time you see a negative headline on the news involving a business, consider whether it will impact its long-term growth prospects and ability to generate a profit. If it doesn't and the stock is down heavily because of the press, that could be a sign that it may be worth taking a contrarian stance on it and buying shares even as it falls in value. It may be a tough decision, but it's one that can pay off later.","news_type":1},"isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":174492824,"gmtCreate":1627121222568,"gmtModify":1703484551017,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like my comment pls&nbsp;","listText":"Like my comment pls&nbsp;","text":"Like my comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/174492824","repostId":"1191636755","repostType":4,"repost":{"id":"1191636755","pubTimestamp":1627084309,"share":"https://www.laohu8.com/m/news/1191636755?lang=&edition=full","pubTime":"2021-07-24 07:51","market":"us","language":"en","title":"Tesla Earnings Are Coming. Here’s the One Number That Matters.","url":"https://stock-news.laohu8.com/highlight/detail?id=1191636755","media":"Barrons","summary":"Tesla’s second-quarter earnings are just around the corner, and investors should gear up for a likel","content":"<p>Tesla’s second-quarter earnings are just around the corner, and investors should gear up for a likely very complicated report.</p>\n<p>There are a lot of moving parts, even more than usual for the world’s most valuable car company and its iconoclast CEO Elon Musk. Figuring out if the stock will go up or down, however, shouldn’t be all that difficult.</p>\n<p>The EV pioneer will report after the close of trading on Monday,July 26. Wall Street is looking for&nbsp;Tesla to report about 94 cents in per-share earnings from $11.5 billion in sales, according to FactSet. Beating analyst estimates is important, almost required, for any stock to remain stable in post-earnings trading. That’s true for Tesla as well.</p>\n<p>There are plenty of factors that will contribute to bottom-line earnings—the global&nbsp;semiconductor&nbsp;shortage,vehicle pricing, vehicle gross profit margins, and the level of profitability in Tesla’s battery storage business. In the end, however, investors will want to see a record in operating profits—no matter how it happens. That’s what could break shares out of their recent range.</p>\n<p><img src=\"https://static.tigerbbs.com/eb9cfd5cbe6d36d06167f82af45447d1\" tg-width=\"869\" tg-height=\"580\" width=\"100%\" height=\"auto\"></p>\n<p>Tesla reported more than $800 million in operating profits in the 2020 third quarter, and the stock more than doubled to around $860 in the three-month span that followed. But since operating profit growth largely paused in the subsequent quarters, shares have traded down from roughly $860 to around $640 recently. Profit stagnation has meant stock stagnation, too.</p>\n<p>The good news for Tesla bulls is Wall Street is projecting a fresh record: Operating profit is expected to be $835 million for the second quarter, driven by strong deliveries. The 2021 second quarter marked the first time Tesla delivered&nbsp;more than 200,000&nbsp;vehicles in a single quarter.</p>\n<p>After earnings are digested, there should be endless arguments among bulls and bears about the quality of earnings. For instance, one way Tesla generates sales is by selling regulatory credits—which it earns by producing more than its fair share of electric vehicles. The company generated $518 million in first-quarter credit sales, which helped Tesla&nbsp;beat earnings&nbsp;estimates. There is always debate about what is the “normal” amount of credit sales and when will those sales dry up. Eventually, both the bulls and bears expect other auto makers to sell their own EVs, cutting off that source of revenue for Tesla.</p>\n<p>There is also the issue&nbsp;of Bitcoin. Tesla recognized a small gain on its Bitcoin holdings in the first quarter, but the cryptocurrency’s prices have fallen by roughly half since their April peak. That means there is a chance of a small loss. How investors react is anyone’s guess, but don’t expect Tesla to sell out of its Bitcoin position. Musk continues to indicate his company will transact in the cryptocurrency when Bitcoin mining uses more sustainable power.</p>\n<p>Investors will also want to know when Tesla’s new Germany plant and Austin, Texas facility will start delivering cars. The Austin plant will build Tesla’s&nbsp;Cybertruck. There will also likely be questions about advances in Tesla’s driver-assistance functions—the company recently started selling its driver-assistance software&nbsp;as a subscription—and how much money the company could make from its charging network. Musk tweeted this week Tesla would open its&nbsp;charging network&nbsp;to other EVs down the road.</p>\n<p>All those topics and more should come up on the earningsconference callscheduled for 5:30 p.m. ET on Monday. Year to date, Tesla stock is down roughly 9%, trailing behind comparable 17% and 15% respective gains of theS&amp;P 500andDow Jones Industrial Average.Still, Tesla shares have had a strong run, up about 112% over the past 12 months.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Earnings Are Coming. Here’s the One Number That Matters.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Earnings Are Coming. Here’s the One Number That Matters.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-24 07:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/tesla-stock-earnings-preview-51627061822?mod=hp_DAY_Theme_2_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla’s second-quarter earnings are just around the corner, and investors should gear up for a likely very complicated report.\nThere are a lot of moving parts, even more than usual for the world’s ...</p>\n\n<a href=\"https://www.barrons.com/articles/tesla-stock-earnings-preview-51627061822?mod=hp_DAY_Theme_2_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.barrons.com/articles/tesla-stock-earnings-preview-51627061822?mod=hp_DAY_Theme_2_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191636755","content_text":"Tesla’s second-quarter earnings are just around the corner, and investors should gear up for a likely very complicated report.\nThere are a lot of moving parts, even more than usual for the world’s most valuable car company and its iconoclast CEO Elon Musk. Figuring out if the stock will go up or down, however, shouldn’t be all that difficult.\nThe EV pioneer will report after the close of trading on Monday,July 26. Wall Street is looking for Tesla to report about 94 cents in per-share earnings from $11.5 billion in sales, according to FactSet. Beating analyst estimates is important, almost required, for any stock to remain stable in post-earnings trading. That’s true for Tesla as well.\nThere are plenty of factors that will contribute to bottom-line earnings—the global semiconductor shortage,vehicle pricing, vehicle gross profit margins, and the level of profitability in Tesla’s battery storage business. In the end, however, investors will want to see a record in operating profits—no matter how it happens. That’s what could break shares out of their recent range.\n\nTesla reported more than $800 million in operating profits in the 2020 third quarter, and the stock more than doubled to around $860 in the three-month span that followed. But since operating profit growth largely paused in the subsequent quarters, shares have traded down from roughly $860 to around $640 recently. Profit stagnation has meant stock stagnation, too.\nThe good news for Tesla bulls is Wall Street is projecting a fresh record: Operating profit is expected to be $835 million for the second quarter, driven by strong deliveries. The 2021 second quarter marked the first time Tesla delivered more than 200,000 vehicles in a single quarter.\nAfter earnings are digested, there should be endless arguments among bulls and bears about the quality of earnings. For instance, one way Tesla generates sales is by selling regulatory credits—which it earns by producing more than its fair share of electric vehicles. The company generated $518 million in first-quarter credit sales, which helped Tesla beat earnings estimates. There is always debate about what is the “normal” amount of credit sales and when will those sales dry up. Eventually, both the bulls and bears expect other auto makers to sell their own EVs, cutting off that source of revenue for Tesla.\nThere is also the issue of Bitcoin. Tesla recognized a small gain on its Bitcoin holdings in the first quarter, but the cryptocurrency’s prices have fallen by roughly half since their April peak. That means there is a chance of a small loss. How investors react is anyone’s guess, but don’t expect Tesla to sell out of its Bitcoin position. Musk continues to indicate his company will transact in the cryptocurrency when Bitcoin mining uses more sustainable power.\nInvestors will also want to know when Tesla’s new Germany plant and Austin, Texas facility will start delivering cars. The Austin plant will build Tesla’s Cybertruck. There will also likely be questions about advances in Tesla’s driver-assistance functions—the company recently started selling its driver-assistance software as a subscription—and how much money the company could make from its charging network. Musk tweeted this week Tesla would open its charging network to other EVs down the road.\nAll those topics and more should come up on the earningsconference callscheduled for 5:30 p.m. ET on Monday. Year to date, Tesla stock is down roughly 9%, trailing behind comparable 17% and 15% respective gains of theS&P 500andDow Jones Industrial Average.Still, Tesla shares have had a strong run, up about 112% over the past 12 months.","news_type":1},"isVote":1,"tweetType":1,"viewCount":55,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":354696795,"gmtCreate":1617164459217,"gmtModify":1704696663723,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like if u long any of them!","listText":"Like if u long any of them!","text":"Like if u long any of them!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/354696795","repostId":"1154884109","repostType":4,"isVote":1,"tweetType":1,"viewCount":78,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175883672,"gmtCreate":1627022167096,"gmtModify":1703482604685,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like my comment pls&nbsp;","listText":"Like my comment pls&nbsp;","text":"Like my comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/175883672","repostId":"1164478982","repostType":4,"repost":{"id":"1164478982","pubTimestamp":1626995319,"share":"https://www.laohu8.com/m/news/1164478982?lang=&edition=full","pubTime":"2021-07-23 07:08","market":"us","language":"en","title":"Wall Street ekes out gains, led by tech, growth stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1164478982","media":"Reuters","summary":"NEW YORK  - Big tech helped Wall Street inch up to a higher close on Thursday, modestly building on a two-day rally as lackluster economic data and mixed corporate earnings prompted a pivot back to growth stocks.A pull-back in economically sensitive cyclicals kept the S&P 500’s and the blue-chip Dow’s gains muted, while small-caps underperformed their larger rivals.“The market is flip-flopping between the view that economic growth has almost peaked so you need to buy stocks that manufacture thei","content":"<p>NEW YORK (Reuters) - Big tech helped Wall Street inch up to a higher close on Thursday, modestly building on a two-day rally as lackluster economic data and mixed corporate earnings prompted a pivot back to growth stocks.</p>\n<p>A pull-back in economically sensitive cyclicals kept the S&amp;P 500’s and the blue-chip Dow’s gains muted, while small-caps underperformed their larger rivals.</p>\n<p>But megacap tech and tech-adjacent stocks, such as Microsoft Corp, Amazon.com, Apple Inc, <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc and Alphabet Inc, rose ahead of their quarterly results next week, putting the Nasdaq out front.</p>\n<p>All three major U.S. stock indexes ended the session within 1% of their record closing highs.</p>\n<p>Growth stocks, which outperformed throughout the health crisis, were back in favor, gaining 0.8%, while the value index slipped by 0.5%.</p>\n<p>“The market is flip-flopping between the view that economic growth has almost peaked so you need to buy stocks that manufacture their own growth like tech names, versus the view that economic growth will continue and you want to own cyclicals and value names,” said David Carter, chief investment officer at Lenox Wealth Advisors in New York.</p>\n<p>The number of U.S. workers filing first-time applications for unemployment benefits spiked unexpectedly to 419,000 last week, a two-month high, according to the Labor Department.</p>\n<p>Market participants are closely watching labor market indicators for hints as to when the Federal Reserve, expected to convene next week for its two-day monetary policy meeting, will begin discussions about hiking key interest rates from near zero.</p>\n<p>“The jobless data today didn’t have a meaningful impact on markets or the economic outlook,” Carter added. “It’s now all about how much longer the Fed will tolerate low rates. The Fed seems to be favoring its full employment mandate more than its price stability mandate.”</p>\n<p>“Accordingly, the upcoming Fed meeting could be impactful,” Carter said.</p>\n<p>Benchmark Treasury yields eased after the bid at the largest-ever TIPS auction touched a record low, pressuring rate sensitive banks.</p>\n<p>The Dow Jones Industrial Average rose 25.35 points, or 0.07%, to 34,823.35, the S&amp;P 500 gained 8.79 points, or 0.20%, to 4,367.48 and the Nasdaq Composite added 52.64 points, or 0.36%, to 14,684.60.</p>\n<p>Of the 11 major sectors of the S&amp;P 500, tech was shining brightest, gaining 0.7%. Energy stocks suffered the largest percentage drop.</p>\n<p>The second-quarter reporting season barreled ahead at full-throttle, with 104 of the companies in the S&amp;P 500 having reported. Of those, 88% have beaten consensus estimates, according to Refinitiv.</p>\n<p>Drugmaker Biogen Inc gained 1.1% after hiking its full-year revenue guidance, while Domino’s Pizza Inc surged 14.6% to an all-time high on the heels of its quarterly report.</p>\n<p>Southwest Airlines Co posted a bigger-than-expected quarterly loss, sending its stock down 3.5%, and American Airlines Group Inc dipped 1.1% even after reporting a quarterly profit.</p>\n<p>The S&amp;P 1500 Airlines index ended the session off 1.7%.</p>\n<p>Shares of Texas Instruments Inc slid 5.3% after its current-quarter revenue forecast cast concerns as to whether the company will be able to meet spiking demand in the face of a global semiconductor shortage.</p>\n<p>The Philadelphia SE Semiconductor index ended the session down 0.9%.</p>\n<p>Chipmaker Intel Corp slipped more than 1% in extended trading after the chipmaker posted results and raised its annual revenue forecast.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.82-to-1 ratio; on Nasdaq, a 1.90-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 39 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 54 new lows.</p>\n<p>Volume on U.S. exchanges was 8.25 billion shares, compared with the 10.12 billion average over the last 20 trading days.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ekes out gains, led by tech, growth stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ekes out gains, led by tech, growth stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/usa-stocks/us-stocks-wall-street-ekes-out-gains-led-by-tech-growth-stocks-idUSL1N2OY2HH><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - Big tech helped Wall Street inch up to a higher close on Thursday, modestly building on a two-day rally as lackluster economic data and mixed corporate earnings prompted a pivot ...</p>\n\n<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-wall-street-ekes-out-gains-led-by-tech-growth-stocks-idUSL1N2OY2HH\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-wall-street-ekes-out-gains-led-by-tech-growth-stocks-idUSL1N2OY2HH","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164478982","content_text":"NEW YORK (Reuters) - Big tech helped Wall Street inch up to a higher close on Thursday, modestly building on a two-day rally as lackluster economic data and mixed corporate earnings prompted a pivot back to growth stocks.\nA pull-back in economically sensitive cyclicals kept the S&P 500’s and the blue-chip Dow’s gains muted, while small-caps underperformed their larger rivals.\nBut megacap tech and tech-adjacent stocks, such as Microsoft Corp, Amazon.com, Apple Inc, Facebook Inc and Alphabet Inc, rose ahead of their quarterly results next week, putting the Nasdaq out front.\nAll three major U.S. stock indexes ended the session within 1% of their record closing highs.\nGrowth stocks, which outperformed throughout the health crisis, were back in favor, gaining 0.8%, while the value index slipped by 0.5%.\n“The market is flip-flopping between the view that economic growth has almost peaked so you need to buy stocks that manufacture their own growth like tech names, versus the view that economic growth will continue and you want to own cyclicals and value names,” said David Carter, chief investment officer at Lenox Wealth Advisors in New York.\nThe number of U.S. workers filing first-time applications for unemployment benefits spiked unexpectedly to 419,000 last week, a two-month high, according to the Labor Department.\nMarket participants are closely watching labor market indicators for hints as to when the Federal Reserve, expected to convene next week for its two-day monetary policy meeting, will begin discussions about hiking key interest rates from near zero.\n“The jobless data today didn’t have a meaningful impact on markets or the economic outlook,” Carter added. “It’s now all about how much longer the Fed will tolerate low rates. The Fed seems to be favoring its full employment mandate more than its price stability mandate.”\n“Accordingly, the upcoming Fed meeting could be impactful,” Carter said.\nBenchmark Treasury yields eased after the bid at the largest-ever TIPS auction touched a record low, pressuring rate sensitive banks.\nThe Dow Jones Industrial Average rose 25.35 points, or 0.07%, to 34,823.35, the S&P 500 gained 8.79 points, or 0.20%, to 4,367.48 and the Nasdaq Composite added 52.64 points, or 0.36%, to 14,684.60.\nOf the 11 major sectors of the S&P 500, tech was shining brightest, gaining 0.7%. Energy stocks suffered the largest percentage drop.\nThe second-quarter reporting season barreled ahead at full-throttle, with 104 of the companies in the S&P 500 having reported. Of those, 88% have beaten consensus estimates, according to Refinitiv.\nDrugmaker Biogen Inc gained 1.1% after hiking its full-year revenue guidance, while Domino’s Pizza Inc surged 14.6% to an all-time high on the heels of its quarterly report.\nSouthwest Airlines Co posted a bigger-than-expected quarterly loss, sending its stock down 3.5%, and American Airlines Group Inc dipped 1.1% even after reporting a quarterly profit.\nThe S&P 1500 Airlines index ended the session off 1.7%.\nShares of Texas Instruments Inc slid 5.3% after its current-quarter revenue forecast cast concerns as to whether the company will be able to meet spiking demand in the face of a global semiconductor shortage.\nThe Philadelphia SE Semiconductor index ended the session down 0.9%.\nChipmaker Intel Corp slipped more than 1% in extended trading after the chipmaker posted results and raised its annual revenue forecast.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.82-to-1 ratio; on Nasdaq, a 1.90-to-1 ratio favored decliners.\nThe S&P 500 posted 39 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 54 new lows.\nVolume on U.S. exchanges was 8.25 billion shares, compared with the 10.12 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":52,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143977916,"gmtCreate":1625758416335,"gmtModify":1703748072964,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like my comment pls&nbsp;","listText":"Like my comment pls&nbsp;","text":"Like my comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/143977916","repostId":"2149328960","repostType":4,"repost":{"id":"2149328960","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1625756309,"share":"https://www.laohu8.com/m/news/2149328960?lang=&edition=full","pubTime":"2021-07-08 22:58","market":"us","language":"en","title":"Wells Fargo Tells Customers It's Shuttering All Personal Lines Of Credit","url":"https://stock-news.laohu8.com/highlight/detail?id=2149328960","media":"Reuters","summary":"Wells Fargo is ending a popular consumer lending product, angering some of its customers, CNBC has l","content":"<p>Wells Fargo&nbsp;is ending a popular consumer lending product, angering some of its customers, CNBC has learned.</p>\n<p>The bank is shutting down all existing personal lines of credit in coming weeks and no longer offers the product, according to customer letters reviewed by CNBC.</p>\n<p>The revolving credit lines, which typically let users borrow $3,000 to $100,000, were pitched as a way to consolidate higher-interest credit-card debt, pay for home renovations or avoid overdraft fees on linked checking accounts.</p>\n<p>\"Wells Fargo recently reviewed its product offerings and decided to discontinue offering new Personal and Portfolio line of credit accounts and close all existing accounts,\" the bank said in the six-page letter. The move would let the bank focus on credit cards and personal loans, it said.</p>\n<p>Wells Fargo CEOCharles Scharfhas been forced to make difficult decisions during the pandemic,offloadingassets and deposits and stepping back from some products because of limitations imposed by the Federal Reserve. In 2018, the Fed barred Wells Fargo from growing its balance sheet until it fixes compliance shortcomings revealed by thebank's fake accounts scandal.</p>\n<p>The asset cap has ultimately cost the bank billions of dollars in lost earnings, based on the balance sheet growth of rivals includingJPMorgan ChaseandBank of Americaover the past three years, analysts havesaid.</p>\n<p>It has also affected Wells Fargo's customers: Last year, the lender told staff it washalting allnew home equity lines of credit, CNBC reported. Months later, the bank also withdrew from a segment of theauto lending business.</p>\n<p>With its latest move, Wells Fargo warned customers that the account closures \"may have an impact on your credit score,\" according to a Frequently Asked Questions segment of the letter.</p>\n<p>Another part of the FAQ asserted that the account closures couldn't be reviewed or reversed: \"We apologize for the inconvenience this Line of Credit closure will cause,\" the bank said. \"The account closure is final.\"</p>\n<p>\"Simplify offerings\"</p>\n<p>Wells Fargo didn't directly answer questions as to what role, if any, the Fed asset cap played in its latest move.</p>\n<p>The bank gave this statement: \"In an effort to simplify our product offerings, we've made the decision to no longer offer personal lines of credit as we feel we can better meet the borrowing needs of our customers through credit card and personal loan products.\"</p>\n<p>Customers have been given a 60-day notice that their accounts will be shuttered, and remaining balances will require regular minimum payments, according to the statement.</p>\n<p>The move is a strange one given the banking industry's need to boost loan growth.</p>\n<p>After a burst of commercial lending during the early days of the pandemic, loan growth has been hard to muster. Corporations have used money raised in stock and debt issuance to retire bank credit lines, and consumers stuck at home had fewer reasons to use credit cards.</p>\n<p>In fact, last year big banks experienced the first aggregate drop in loans in more than a decade,accordingto Barclays bank analyst Jason Goldberg. Of the four largest U.S. banks, Wells Fargo saw the worst decline.</p>\n<p>After banks saw that borrowers held up far better than they had initially feared, the industry recently began marketingnew credit cardswith large sign-on bonuses in an effort to boost lending.</p>\n<p>Making the switch</p>\n<p>Wells Fargo doesn't disclose how many customers used the credit lines it is eliminating. It had$24.9 billionin loans in a category called \"other consumer\" as of March, which was 26% lower than the year-earlier period.</p>\n<p>One customer said the change is prompting him to switch banks after more than a decade with Wells Fargo. Tim Tomassi, a Portland, Oregon programmer, said that he used a personal line of credit linked to his checking account to avoid expensive overdraft fees.</p>\n<p>\"It's a bit upsetting,\" Tomassi said in a phone interview. \"They're a big bank, and I'm a small person, and it feels like they're making decisions for their bottom line and not for customers. A lot of people are in my position, they need a cushion every once in a while from a line of credit.\"</p>\n<p>Tomassi said he is considering opening an account at&nbsp;Allyor&nbsp;Chime, banking players that don't chargeoverdraft fees.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wells Fargo Tells Customers It's Shuttering All Personal Lines Of Credit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWells Fargo Tells Customers It's Shuttering All Personal Lines Of Credit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-08 22:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Wells Fargo&nbsp;is ending a popular consumer lending product, angering some of its customers, CNBC has learned.</p>\n<p>The bank is shutting down all existing personal lines of credit in coming weeks and no longer offers the product, according to customer letters reviewed by CNBC.</p>\n<p>The revolving credit lines, which typically let users borrow $3,000 to $100,000, were pitched as a way to consolidate higher-interest credit-card debt, pay for home renovations or avoid overdraft fees on linked checking accounts.</p>\n<p>\"Wells Fargo recently reviewed its product offerings and decided to discontinue offering new Personal and Portfolio line of credit accounts and close all existing accounts,\" the bank said in the six-page letter. The move would let the bank focus on credit cards and personal loans, it said.</p>\n<p>Wells Fargo CEOCharles Scharfhas been forced to make difficult decisions during the pandemic,offloadingassets and deposits and stepping back from some products because of limitations imposed by the Federal Reserve. In 2018, the Fed barred Wells Fargo from growing its balance sheet until it fixes compliance shortcomings revealed by thebank's fake accounts scandal.</p>\n<p>The asset cap has ultimately cost the bank billions of dollars in lost earnings, based on the balance sheet growth of rivals includingJPMorgan ChaseandBank of Americaover the past three years, analysts havesaid.</p>\n<p>It has also affected Wells Fargo's customers: Last year, the lender told staff it washalting allnew home equity lines of credit, CNBC reported. Months later, the bank also withdrew from a segment of theauto lending business.</p>\n<p>With its latest move, Wells Fargo warned customers that the account closures \"may have an impact on your credit score,\" according to a Frequently Asked Questions segment of the letter.</p>\n<p>Another part of the FAQ asserted that the account closures couldn't be reviewed or reversed: \"We apologize for the inconvenience this Line of Credit closure will cause,\" the bank said. \"The account closure is final.\"</p>\n<p>\"Simplify offerings\"</p>\n<p>Wells Fargo didn't directly answer questions as to what role, if any, the Fed asset cap played in its latest move.</p>\n<p>The bank gave this statement: \"In an effort to simplify our product offerings, we've made the decision to no longer offer personal lines of credit as we feel we can better meet the borrowing needs of our customers through credit card and personal loan products.\"</p>\n<p>Customers have been given a 60-day notice that their accounts will be shuttered, and remaining balances will require regular minimum payments, according to the statement.</p>\n<p>The move is a strange one given the banking industry's need to boost loan growth.</p>\n<p>After a burst of commercial lending during the early days of the pandemic, loan growth has been hard to muster. Corporations have used money raised in stock and debt issuance to retire bank credit lines, and consumers stuck at home had fewer reasons to use credit cards.</p>\n<p>In fact, last year big banks experienced the first aggregate drop in loans in more than a decade,accordingto Barclays bank analyst Jason Goldberg. Of the four largest U.S. banks, Wells Fargo saw the worst decline.</p>\n<p>After banks saw that borrowers held up far better than they had initially feared, the industry recently began marketingnew credit cardswith large sign-on bonuses in an effort to boost lending.</p>\n<p>Making the switch</p>\n<p>Wells Fargo doesn't disclose how many customers used the credit lines it is eliminating. It had$24.9 billionin loans in a category called \"other consumer\" as of March, which was 26% lower than the year-earlier period.</p>\n<p>One customer said the change is prompting him to switch banks after more than a decade with Wells Fargo. Tim Tomassi, a Portland, Oregon programmer, said that he used a personal line of credit linked to his checking account to avoid expensive overdraft fees.</p>\n<p>\"It's a bit upsetting,\" Tomassi said in a phone interview. \"They're a big bank, and I'm a small person, and it feels like they're making decisions for their bottom line and not for customers. A lot of people are in my position, they need a cushion every once in a while from a line of credit.\"</p>\n<p>Tomassi said he is considering opening an account at&nbsp;Allyor&nbsp;Chime, banking players that don't chargeoverdraft fees.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CUBI":"Customers Bancorp Inc.","WFC":"富国银行"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2149328960","content_text":"Wells Fargo is ending a popular consumer lending product, angering some of its customers, CNBC has learned.\nThe bank is shutting down all existing personal lines of credit in coming weeks and no longer offers the product, according to customer letters reviewed by CNBC.\nThe revolving credit lines, which typically let users borrow $3,000 to $100,000, were pitched as a way to consolidate higher-interest credit-card debt, pay for home renovations or avoid overdraft fees on linked checking accounts.\n\"Wells Fargo recently reviewed its product offerings and decided to discontinue offering new Personal and Portfolio line of credit accounts and close all existing accounts,\" the bank said in the six-page letter. The move would let the bank focus on credit cards and personal loans, it said.\nWells Fargo CEOCharles Scharfhas been forced to make difficult decisions during the pandemic,offloadingassets and deposits and stepping back from some products because of limitations imposed by the Federal Reserve. In 2018, the Fed barred Wells Fargo from growing its balance sheet until it fixes compliance shortcomings revealed by thebank's fake accounts scandal.\nThe asset cap has ultimately cost the bank billions of dollars in lost earnings, based on the balance sheet growth of rivals includingJPMorgan ChaseandBank of Americaover the past three years, analysts havesaid.\nIt has also affected Wells Fargo's customers: Last year, the lender told staff it washalting allnew home equity lines of credit, CNBC reported. Months later, the bank also withdrew from a segment of theauto lending business.\nWith its latest move, Wells Fargo warned customers that the account closures \"may have an impact on your credit score,\" according to a Frequently Asked Questions segment of the letter.\nAnother part of the FAQ asserted that the account closures couldn't be reviewed or reversed: \"We apologize for the inconvenience this Line of Credit closure will cause,\" the bank said. \"The account closure is final.\"\n\"Simplify offerings\"\nWells Fargo didn't directly answer questions as to what role, if any, the Fed asset cap played in its latest move.\nThe bank gave this statement: \"In an effort to simplify our product offerings, we've made the decision to no longer offer personal lines of credit as we feel we can better meet the borrowing needs of our customers through credit card and personal loan products.\"\nCustomers have been given a 60-day notice that their accounts will be shuttered, and remaining balances will require regular minimum payments, according to the statement.\nThe move is a strange one given the banking industry's need to boost loan growth.\nAfter a burst of commercial lending during the early days of the pandemic, loan growth has been hard to muster. Corporations have used money raised in stock and debt issuance to retire bank credit lines, and consumers stuck at home had fewer reasons to use credit cards.\nIn fact, last year big banks experienced the first aggregate drop in loans in more than a decade,accordingto Barclays bank analyst Jason Goldberg. Of the four largest U.S. banks, Wells Fargo saw the worst decline.\nAfter banks saw that borrowers held up far better than they had initially feared, the industry recently began marketingnew credit cardswith large sign-on bonuses in an effort to boost lending.\nMaking the switch\nWells Fargo doesn't disclose how many customers used the credit lines it is eliminating. It had$24.9 billionin loans in a category called \"other consumer\" as of March, which was 26% lower than the year-earlier period.\nOne customer said the change is prompting him to switch banks after more than a decade with Wells Fargo. Tim Tomassi, a Portland, Oregon programmer, said that he used a personal line of credit linked to his checking account to avoid expensive overdraft fees.\n\"It's a bit upsetting,\" Tomassi said in a phone interview. \"They're a big bank, and I'm a small person, and it feels like they're making decisions for their bottom line and not for customers. A lot of people are in my position, they need a cushion every once in a while from a line of credit.\"\nTomassi said he is considering opening an account at Allyor Chime, banking players that don't chargeoverdraft fees.","news_type":1},"isVote":1,"tweetType":1,"viewCount":46,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":181266681,"gmtCreate":1623397074843,"gmtModify":1704202491949,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like my comment pls&nbsp;","listText":"Like my comment pls&nbsp;","text":"Like my comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/181266681","repostId":"1152092787","repostType":4,"repost":{"id":"1152092787","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623395464,"share":"https://www.laohu8.com/m/news/1152092787?lang=&edition=full","pubTime":"2021-06-11 15:11","market":"us","language":"en","title":"Tesla Begins Deliveries Of Model S Plaid: Everything You Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=1152092787","media":"Benzinga","summary":"Tesla Inc TSLA 1.89%has begun delivering its Model S Plaid electric vehicle, as per CEO Elon Musk.\nW","content":"<p><b>Tesla Inc</b>&nbsp;TSLA 1.89%has begun delivering its Model S Plaid electric vehicle, as per CEO Elon Musk.</p>\n<p><b>What Happened:</b>&nbsp;Musk made the announcement at adelivery event that was live-streamed&nbsp;on Thursday night.</p>\n<p>As per the Tesla website, the 1,020 horsepower vehicle is on sale for $129,990, excluding any potential savings.</p>\n<p>The vehicle was shown off at the delivery event Thursday by Musk and Tesla’s Senior Design Executive Franz von Holzhausen.</p>\n<p>Musk took to Twitter to talk about the four-door sedan. He called Tesla’s engineering “awesome” in a tweet and said he “loved the yoke” steering wheel of the vehicle.</p>\n<p><img src=\"https://static.tigerbbs.com/6bd55a20f1a5b442e5858c18c5e1c730\" tg-width=\"562\" tg-height=\"316\">Praising the vehicle, Musksaidon Twitter that the Plaid S was the “most amount of fun on 4 wheels!” — adding, “Pure joy on tap whenever u want.”</p>\n<p>The Tesla CEO announced that deliveries have commenced with the first 25 vehicles to be delivered immediately. The volume will reach several hundred units per week “soon,” and 1000 cars per week the next quarter, Musk&nbsp;said at the event.</p>\n<p><b>Why It Matters:</b>&nbsp;Musk touted the car’s “crazy performance” during Thursday’s delivery event and claimed that the vehicle had a 390-mile range. On Plaid’s acceleration capabilities, Musk said, “No production car has done 0-60 under 2 seconds.”</p>\n<p>The top speed of the vehicle is 200 mph and it can charge 187 miles in 15 minutes.</p>\n<p>Musk also said Tesla will do \"waypoints\" owing to high demand, which would allow users to enter multiple destinations in a single trip within Tesla's navigation system.</p>\n<p>Calling the vehicle a “good looking sports car,” Musk said that Tesla was able to achieve the lowest drag coefficient of any production car ever made.</p>\n<p>Also shown Thursday were the car’s interiors which feature ventilated front seats,&nbsp;more room for the backseat, and invisible air conditioning.</p>\n<p>There are chargers in the back and front seats for phones and other devices and the vehicle features a landscape touchscreen for video playback and gaming.</p>\n<p>On gaming, Musk touted a “PS5-level performance” and said users can play state of the art games at 60 frames per second.</p>\n<p>Tesla hascanceled the Plus modelof the Plaid range. Musk said earlier this week that the latest version is “just so good.”</p>\n<p><b>Price Action:</b>&nbsp;On Thursday, Tesla shares closed nearly 1.9% higher at $610.12 and fell 0.35% in the after-hours session.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Begins Deliveries Of Model S Plaid: Everything You Need To Know</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Begins Deliveries Of Model S Plaid: Everything You Need To Know\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-11 15:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Tesla Inc</b>&nbsp;TSLA 1.89%has begun delivering its Model S Plaid electric vehicle, as per CEO Elon Musk.</p>\n<p><b>What Happened:</b>&nbsp;Musk made the announcement at adelivery event that was live-streamed&nbsp;on Thursday night.</p>\n<p>As per the Tesla website, the 1,020 horsepower vehicle is on sale for $129,990, excluding any potential savings.</p>\n<p>The vehicle was shown off at the delivery event Thursday by Musk and Tesla’s Senior Design Executive Franz von Holzhausen.</p>\n<p>Musk took to Twitter to talk about the four-door sedan. He called Tesla’s engineering “awesome” in a tweet and said he “loved the yoke” steering wheel of the vehicle.</p>\n<p><img src=\"https://static.tigerbbs.com/6bd55a20f1a5b442e5858c18c5e1c730\" tg-width=\"562\" tg-height=\"316\">Praising the vehicle, Musksaidon Twitter that the Plaid S was the “most amount of fun on 4 wheels!” — adding, “Pure joy on tap whenever u want.”</p>\n<p>The Tesla CEO announced that deliveries have commenced with the first 25 vehicles to be delivered immediately. The volume will reach several hundred units per week “soon,” and 1000 cars per week the next quarter, Musk&nbsp;said at the event.</p>\n<p><b>Why It Matters:</b>&nbsp;Musk touted the car’s “crazy performance” during Thursday’s delivery event and claimed that the vehicle had a 390-mile range. On Plaid’s acceleration capabilities, Musk said, “No production car has done 0-60 under 2 seconds.”</p>\n<p>The top speed of the vehicle is 200 mph and it can charge 187 miles in 15 minutes.</p>\n<p>Musk also said Tesla will do \"waypoints\" owing to high demand, which would allow users to enter multiple destinations in a single trip within Tesla's navigation system.</p>\n<p>Calling the vehicle a “good looking sports car,” Musk said that Tesla was able to achieve the lowest drag coefficient of any production car ever made.</p>\n<p>Also shown Thursday were the car’s interiors which feature ventilated front seats,&nbsp;more room for the backseat, and invisible air conditioning.</p>\n<p>There are chargers in the back and front seats for phones and other devices and the vehicle features a landscape touchscreen for video playback and gaming.</p>\n<p>On gaming, Musk touted a “PS5-level performance” and said users can play state of the art games at 60 frames per second.</p>\n<p>Tesla hascanceled the Plus modelof the Plaid range. Musk said earlier this week that the latest version is “just so good.”</p>\n<p><b>Price Action:</b>&nbsp;On Thursday, Tesla shares closed nearly 1.9% higher at $610.12 and fell 0.35% in the after-hours session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152092787","content_text":"Tesla Inc TSLA 1.89%has begun delivering its Model S Plaid electric vehicle, as per CEO Elon Musk.\nWhat Happened: Musk made the announcement at adelivery event that was live-streamed on Thursday night.\nAs per the Tesla website, the 1,020 horsepower vehicle is on sale for $129,990, excluding any potential savings.\nThe vehicle was shown off at the delivery event Thursday by Musk and Tesla’s Senior Design Executive Franz von Holzhausen.\nMusk took to Twitter to talk about the four-door sedan. He called Tesla’s engineering “awesome” in a tweet and said he “loved the yoke” steering wheel of the vehicle.\nPraising the vehicle, Musksaidon Twitter that the Plaid S was the “most amount of fun on 4 wheels!” — adding, “Pure joy on tap whenever u want.”\nThe Tesla CEO announced that deliveries have commenced with the first 25 vehicles to be delivered immediately. The volume will reach several hundred units per week “soon,” and 1000 cars per week the next quarter, Musk said at the event.\nWhy It Matters: Musk touted the car’s “crazy performance” during Thursday’s delivery event and claimed that the vehicle had a 390-mile range. On Plaid’s acceleration capabilities, Musk said, “No production car has done 0-60 under 2 seconds.”\nThe top speed of the vehicle is 200 mph and it can charge 187 miles in 15 minutes.\nMusk also said Tesla will do \"waypoints\" owing to high demand, which would allow users to enter multiple destinations in a single trip within Tesla's navigation system.\nCalling the vehicle a “good looking sports car,” Musk said that Tesla was able to achieve the lowest drag coefficient of any production car ever made.\nAlso shown Thursday were the car’s interiors which feature ventilated front seats, more room for the backseat, and invisible air conditioning.\nThere are chargers in the back and front seats for phones and other devices and the vehicle features a landscape touchscreen for video playback and gaming.\nOn gaming, Musk touted a “PS5-level performance” and said users can play state of the art games at 60 frames per second.\nTesla hascanceled the Plus modelof the Plaid range. Musk said earlier this week that the latest version is “just so good.”\nPrice Action: On Thursday, Tesla shares closed nearly 1.9% higher at $610.12 and fell 0.35% in the after-hours session.","news_type":1},"isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3581631227222192","authorId":"3581631227222192","name":"Mythology","avatar":"https://static.tigerbbs.com/190cafdd30075e07fb377edd392ed682","crmLevel":2,"crmLevelSwitch":0},"content":"Pls Comment me vack:)","text":"Pls Comment me vack:)","html":"Pls Comment me vack:)"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119379521,"gmtCreate":1622523353063,"gmtModify":1704185595757,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like my comment pls","listText":"Like my comment pls","text":"Like my comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/119379521","repostId":"1105273964","repostType":4,"repost":{"id":"1105273964","pubTimestamp":1622511256,"share":"https://www.laohu8.com/m/news/1105273964?lang=&edition=full","pubTime":"2021-06-01 09:34","market":"hk","language":"en","title":"Here Are the 11 Best Performing IPOs of the Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1105273964","media":"Barron's","summary":"The market for initial public offerings has recently delivered some great first-day gains for investors who were able to get shares before the companies went public.That left us with 11 names. First up:CureVac, which was the screen’s best-performing IPO and had a total return of 596.75%. CureVac specializes in the messenger RNA, or mRNA, technology that is the basis of several leading Covid-19 vaccine programs. The German biotech company went public inAugust at $16 a shareand soared 249% in its ","content":"<p>The market for initial public offerings has recently delivered some great first-day gains for investors who were able to get shares before the companies went public.</p><p>But not everyone receives these types of opportunities. Most retail investors have to wait until companies start publicly trading to buy stock.<i>Barron’s</i>looked at businesses that have gone public in the past 12 months to find some strong performers.</p><p>First, we searched for companies that listed via a traditional initial public offering: This meant we filtered out businesses that merged withspecial purpose acquisition companies, or SPACs. Then, we searched for companies that went public on either the New York Stock Exchange or the Nasdaq. We also focused on entities that had at least a $1 billion market capitalization. We narrowed our search to companies with the highesttotal returns from their stock offering prices..</p><p>That left us with 11 names. First up:CureVac(ticker: CVAC), which was the screen’s best-performing IPO and had a total return of 596.75%. CureVac specializes in the messenger RNA, or mRNA, technology that is the basis of several leading Covid-19 vaccine programs. The German biotech company went public inAugust at $16 a shareand soared 249% in its first day, with the stock closing at $55.90. In January, CureVacstruck a deal with Bayerto accelerate the development and supply of its Covid-19 vaccine candidate. The company’s mRNA-based Covid-19 vaccine is now in clinical trials, and Phase2b/3 data is expected this summer. Since its IPO, the stock has nearly doubled, closingFriday at $111.48 .</p><p>Strong performances need not be dictated by success on the first day of trading. Four of the companies that made our list were busted deals—meaning that their shares fell below their IPO prices on the first day of trading.</p><p>Case in point:ZIM Integrated Shipping(ZIM). The asset-light shipping company went public in January with a $15 offering price,but closed that day at $11.50. Yet by May 19, ZIM’s stockhad gained 295%after itreported first-quarter earnings of $589.6 million, or $5.35 a share. The companyalso declared a special cash dividend of $2 a share. ZIM is the second-best-performing IPO in the past 12 months, based on a total return of 209.33%, according to FactSet. It closed on Friday at $46.40.</p><p>Another example isAcademy Sports &amp; Outdoors(ASO): The companywent public in Octoberwith a $13 offering price, with the stock closing at $12.99 during its first day of public trading<b>.</b>Academy was profitable when it went public, a rarity in the IPO market. InMarch, the company reported that its net incomesoared 416%, to $91.5 million, or 97 cents a share, for its fourth fiscal quarter ended Jan. 30. Its shares have nearly tripled since the IPO, and were trading at $36.53 on Friday. Academy Sports ranks third with a total return from the offering price of 181%, FactSet said.</p><p>Strong GainersThese companies all went public in the last year and produced high total returns compared to their IPO prices.<img src=\"https://static.tigerbbs.com/9dedc209ede147958c015d3a586bb587\" tg-width=\"630\" tg-height=\"606\">Rounding out this category areCorsair Gaming(CRSR), a California companythat makes performance gear for gamers, and the Dubai-basedYalla Group(YALA), whichmakes a voice-chat app usedin the Middle East and North Africa called Yalla. Both stocks have rebounded strongly after less-than-stellar September IPOs.</p><p>Some companies that made our list soared during their debuts, but have since seen their shares retreat. Still, these companies are producing gains.</p><p>ConsiderBigCommerce(BIGC), which provides a cloud e-commerce platform that is used by such customers as SkullCandy, Savannah Bee Co, and the Cleveland Cavaliers.BigCommerce&nbsp;went public in Augustwith a $24 offering price—and the stock soared 201% that day,closing at $72.27. Since the IPO, the shares have fallen nearly 25%, amid a broader technology selloff.</p><p>The company, however, has reported some positive developments, like a deal in February that wouldgive BigCommerce customersthe ability to sell directly on Walmart Marketplace. It also reported better-than-expected fourth-quarter results. BigCommerce has produced a total return of nearly 127%, according to FactSet.</p><p>Other companies have seen their shares jump since going public.Dream Finders Homes (DFH), which designs, builds, and sells homes in high-growth markets, was already profitable when it made its trading debut in January at $13 a share. Shares soared 61%, $20.95 on its first day.Prices for houses in Marchgrew at the fastest rate since 2005, which has helped real estate stocks. Dream Finders stock has gained nearly 52% since its IPO, trading Friday at $31.77. Dream Finders notched a total return from offering price of 144.38%.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here Are the 11 Best Performing IPOs of the Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere Are the 11 Best Performing IPOs of the Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/here-are-the-11-best-performing-ipos-of-the-year-51622472529?mod=hp_DAY_0><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The market for initial public offerings has recently delivered some great first-day gains for investors who were able to get shares before the companies went public.But not everyone receives these ...</p>\n\n<a href=\"https://www.barrons.com/articles/here-are-the-11-best-performing-ipos-of-the-year-51622472529?mod=hp_DAY_0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.barrons.com/articles/here-are-the-11-best-performing-ipos-of-the-year-51622472529?mod=hp_DAY_0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105273964","content_text":"The market for initial public offerings has recently delivered some great first-day gains for investors who were able to get shares before the companies went public.But not everyone receives these types of opportunities. Most retail investors have to wait until companies start publicly trading to buy stock.Barron’slooked at businesses that have gone public in the past 12 months to find some strong performers.First, we searched for companies that listed via a traditional initial public offering: This meant we filtered out businesses that merged withspecial purpose acquisition companies, or SPACs. Then, we searched for companies that went public on either the New York Stock Exchange or the Nasdaq. We also focused on entities that had at least a $1 billion market capitalization. We narrowed our search to companies with the highesttotal returns from their stock offering prices..That left us with 11 names. First up:CureVac(ticker: CVAC), which was the screen’s best-performing IPO and had a total return of 596.75%. CureVac specializes in the messenger RNA, or mRNA, technology that is the basis of several leading Covid-19 vaccine programs. The German biotech company went public inAugust at $16 a shareand soared 249% in its first day, with the stock closing at $55.90. In January, CureVacstruck a deal with Bayerto accelerate the development and supply of its Covid-19 vaccine candidate. The company’s mRNA-based Covid-19 vaccine is now in clinical trials, and Phase2b/3 data is expected this summer. Since its IPO, the stock has nearly doubled, closingFriday at $111.48 .Strong performances need not be dictated by success on the first day of trading. Four of the companies that made our list were busted deals—meaning that their shares fell below their IPO prices on the first day of trading.Case in point:ZIM Integrated Shipping(ZIM). The asset-light shipping company went public in January with a $15 offering price,but closed that day at $11.50. Yet by May 19, ZIM’s stockhad gained 295%after itreported first-quarter earnings of $589.6 million, or $5.35 a share. The companyalso declared a special cash dividend of $2 a share. ZIM is the second-best-performing IPO in the past 12 months, based on a total return of 209.33%, according to FactSet. It closed on Friday at $46.40.Another example isAcademy Sports & Outdoors(ASO): The companywent public in Octoberwith a $13 offering price, with the stock closing at $12.99 during its first day of public trading.Academy was profitable when it went public, a rarity in the IPO market. InMarch, the company reported that its net incomesoared 416%, to $91.5 million, or 97 cents a share, for its fourth fiscal quarter ended Jan. 30. Its shares have nearly tripled since the IPO, and were trading at $36.53 on Friday. Academy Sports ranks third with a total return from the offering price of 181%, FactSet said.Strong GainersThese companies all went public in the last year and produced high total returns compared to their IPO prices.Rounding out this category areCorsair Gaming(CRSR), a California companythat makes performance gear for gamers, and the Dubai-basedYalla Group(YALA), whichmakes a voice-chat app usedin the Middle East and North Africa called Yalla. Both stocks have rebounded strongly after less-than-stellar September IPOs.Some companies that made our list soared during their debuts, but have since seen their shares retreat. Still, these companies are producing gains.ConsiderBigCommerce(BIGC), which provides a cloud e-commerce platform that is used by such customers as SkullCandy, Savannah Bee Co, and the Cleveland Cavaliers.BigCommerce went public in Augustwith a $24 offering price—and the stock soared 201% that day,closing at $72.27. Since the IPO, the shares have fallen nearly 25%, amid a broader technology selloff.The company, however, has reported some positive developments, like a deal in February that wouldgive BigCommerce customersthe ability to sell directly on Walmart Marketplace. It also reported better-than-expected fourth-quarter results. BigCommerce has produced a total return of nearly 127%, according to FactSet.Other companies have seen their shares jump since going public.Dream Finders Homes (DFH), which designs, builds, and sells homes in high-growth markets, was already profitable when it made its trading debut in January at $13 a share. Shares soared 61%, $20.95 on its first day.Prices for houses in Marchgrew at the fastest rate since 2005, which has helped real estate stocks. Dream Finders stock has gained nearly 52% since its IPO, trading Friday at $31.77. Dream Finders notched a total return from offering price of 144.38%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":64,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":379658963,"gmtCreate":1618732941552,"gmtModify":1704714438565,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like my comment pls","listText":"Like my comment pls","text":"Like my comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/379658963","repostId":"1165321503","repostType":4,"repost":{"id":"1165321503","pubTimestamp":1618588143,"share":"https://www.laohu8.com/m/news/1165321503?lang=&edition=full","pubTime":"2021-04-16 23:49","market":"us","language":"en","title":"Fed’s Waller says the economy is ‘ready to rip’ but policy should stay put","url":"https://stock-news.laohu8.com/highlight/detail?id=1165321503","media":"cnbc","summary":"KEY POINTSFed Governor Christopher Waller told CNBC on Friday that the economy “is ready to rip.Howe","content":"<div>\n<p>KEY POINTSFed Governor Christopher Waller told CNBC on Friday that the economy “is ready to rip.However, he said there’s still “no reason to be pulling the plug” on the heavy levels of policy support ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/16/feds-waller-says-the-economy-is-ready-to-rip-but-policy-should-stay-put.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fed’s Waller says the economy is ‘ready to rip’ but policy should stay put</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFed’s Waller says the economy is ‘ready to rip’ but policy should stay put\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 23:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/16/feds-waller-says-the-economy-is-ready-to-rip-but-policy-should-stay-put.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTSFed Governor Christopher Waller told CNBC on Friday that the economy “is ready to rip.However, he said there’s still “no reason to be pulling the plug” on the heavy levels of policy support ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/16/feds-waller-says-the-economy-is-ready-to-rip-but-policy-should-stay-put.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index","SPY":"标普500ETF",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.cnbc.com/2021/04/16/feds-waller-says-the-economy-is-ready-to-rip-but-policy-should-stay-put.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1165321503","content_text":"KEY POINTSFed Governor Christopher Waller told CNBC on Friday that the economy “is ready to rip.However, he said there’s still “no reason to be pulling the plug” on the heavy levels of policy support the central bank is providing.Waller said he also expects inflationary pressures to be temporary, though he forecasts 2021 to run at 2.5%, well above the Fed’s 2% target.Federal Reserve Governor Christopher Waller said Friday he sees the U.S. economy as set to take off, though not at a fast enough pace that the central bank should start tightening policy.\"I think the economy is ready to rip,\" Waller told CNBC'sSteve Liesmanduring a \"Squawk on the Street\" interview. \"There's still more to do on that, but I think everyone's getting a lot more comfortable with having the virus under control and we're starting to see it in the form of economic activity.\"Those comments came amid a decidedly upward move in economic data.In March alone, nonfarmpayrolls jumped by 916,000, retail sales sawa 9.8% stimulus-fueled boom, and multiple manufacturing gauges reached their highest levels in years.There are further indications that job growth continued into April, with jobless claims last week tumbling to 576,000, easily the lowest level since the early days of the pandemic.Coupled all that witha vaccination pacein excess of the 3 million a day, and it adds up to a strong outlook, Waller said.“We can get the virus pretty much under control. We get 70% of the population vaccinated, then all the fundamentals are there for good, strong growth that we left back in January, February of 2020,” he said. “We’ve still got room to catch up to where we were. We’re making up for lost ground.”‘No reason to be pulling the plug’The economy officially entered recession in February 2020, according to the National Bureau of Economic Research, which makes the official call on contractions and expansions. While the U.S. is poised for another quarter of strong growth, gross domestic product is still running a bit below where it was prior to the Covid-19 onset.That’s part of the reason Waller concurs with his fellow central bankers in seeingthe need to keep policy loose. The Fed is currently holding short-term borrowing rates near zero while it purchases at least $120 billion of bonds each month.In a major policy shift last year, the Fed pledged that it will not raise rates until it sees full and inclusive employment, and is willing to tolerate inflation a bit above the traditional 2% target until it gets there. Fed officials have expressed concern about the uneven nature of the recovery, particularly regarding those at the lower end of the income spectrum.“We’ve got to make that up first,” Waller said. “Other parts of the economy seem to have really come back. We still have relatively high unemployment rates, particularly for minorities, and so we’ve still got a long way to go. There’s no reason to be pulling the plug on our support till we’re really through this.”Waller added that he thinks inflationary pressures that have begun to show up are likely temporary, a view widely held at the Fed. The consumer price index rose 2.6% in March from a year ago.Waller said he expects the Fed’s preferred inflation gauge based on personal consumption expenditures could run around 2.5% for 2021.","news_type":1},"isVote":1,"tweetType":1,"viewCount":141,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178165772,"gmtCreate":1626792556096,"gmtModify":1703765354912,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like my comment pls","listText":"Like my comment pls","text":"Like my comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/178165772","repostId":"1199016731","repostType":4,"repost":{"id":"1199016731","pubTimestamp":1626790980,"share":"https://www.laohu8.com/m/news/1199016731?lang=&edition=full","pubTime":"2021-07-20 22:23","market":"us","language":"en","title":"Coronavirus Stocks Are Zooming Higher Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1199016731","media":"Motley Fool","summary":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and p","content":"<blockquote>\n The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n</blockquote>\n<p>(July 20)&nbsp;Coronavirus Stocks Are Zooming Higher Today.</p>\n<p><img src=\"https://static.tigerbbs.com/904717ccbe2ab812494060e6506f15df\" tg-width=\"302\" tg-height=\"402\" referrerpolicy=\"no-referrer\"></p>\n<p><b>So what</b></p>\n<p>The key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According to<i>New York Times</i>data, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.</p>\n<p>So the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(<b>Pfizer</b>) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.</p>\n<p><b>Now what</b></p>\n<p>If the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.</p>\n<p>Novavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coronavirus Stocks Are Zooming Higher Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoronavirus Stocks Are Zooming Higher Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 22:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNY":"赛诺菲安万特","BNTX":"BioNTech SE","PFE":"辉瑞","JNJ":"强生","NVAX":"诺瓦瓦克斯医药","AZN":"阿斯利康","MRK":"默沙东","CVAC":"CureVac B.V.","MRNA":"Moderna, Inc.","GSK":"葛兰素史克"},"source_url":"https://www.fool.com/investing/2021/07/19/why-coronavirus-stocks-are-zooming-higher-today/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199016731","content_text":"The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.\n\n(July 20) Coronavirus Stocks Are Zooming Higher Today.\n\nSo what\nThe key reason for these increases is simple: Because of its powerful delta variant, the coronavirus is very much on the rise again. According toNew York Timesdata, statistics from Sunday indicate the 14-day change in new cases in the U.S. was a worrying 140% increase, with fatalities rising 33%.\nSo the need for a harder and wider vaccine push is obvious; such a move would clearly benefit both Moderna and BioNTech. These companies (including BioNTech partner(Pfizer) provide two of only three coronavirus vaccines authorized by the Food and Drug Administration. It should also help Co-Diagnostics, which is a high-profile maker of a COVID-19 testing product.\nNow what\nIf the coronavirus surge continues, it's very possible we'll face an \"all hands on deck,\" situation with vaccines. Perhaps the ones being developed by vaccine-focusedbiotechsNovavax and Vaxart will be authorized by the FDA.\nNovavax plans to file for Emergency Use Authorization for itsNVX-CoV2373this quarter, and Vaxart will certainly be on investors' radar due to the oral vaccine it's currently developing -- despite the fact that this program has attracted itsshare of controversy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":52,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103821380,"gmtCreate":1619769258140,"gmtModify":1704272100350,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Reply my comment pls","listText":"Reply my comment pls","text":"Reply my comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/103821380","repostId":"1109392198","repostType":4,"repost":{"id":"1109392198","pubTimestamp":1619767381,"share":"https://www.laohu8.com/m/news/1109392198?lang=&edition=full","pubTime":"2021-04-30 15:23","market":"us","language":"en","title":"Tesla Stock Has Many Risks. EV Credits Isn’t One of Them.","url":"https://stock-news.laohu8.com/highlight/detail?id=1109392198","media":"Barrons","summary":"Tesla bears need to stop harping on regulatory credit sales. The oft-repeated refrain is that Tesla ","content":"<p>Tesla bears need to stop harping on regulatory credit sales. The oft-repeated refrain is that Tesla isn’t profitable without credit sales. There are plenty of reasons bears can avoid Tesla stock, but credits Tesla earns, and then sells for cash to other auto makers, for producing more than its shares of zero emission vehicles isn’t one of them.</p><p>Tesla sold more than $500 million in regulatory credits in the&nbsp;first quarter&nbsp;and generated just under $600 million in operating profit. Excluding the credits, Tesla only eked out a small operating profit.</p><p>But saying Tesla isn’t profitable without regulatory credits is falling victim to the fallacy of the predetermined outcome. It’s like saying the New York Jets lost a football game because of a bad call in the first quarter. There are many reasons the Jets lose and a refereeing mistakes aren’t one of them.</p><p>To drive the analogy further, any Jets game would be totally different if the ref didn’t mess up. A penalty not called, or called, changes each subsequent play in unknown ways. If Tesla didn’t have regulatory credits to sell, the company would have to raise prices or cut costs or do something else to make money. The company would adapt to the situation.</p><p>Raising prices could be a way to go, but higher prices, of course, have their own impact, potentially reducing demand. Tesla still managed to grow sales even after the company lost its $7,500 U.S. federal&nbsp;tax credit. That isn’t available to Tesla buyers any longer because Tesla has sold too many EVs to qualify.</p><p>Tesla lost that federal credit at the end of 2019. It was effectively a $7,500 price increase in the U.S. on Jan. 1, 2020. Tesla sales in the U.S. grew 20% this past year, hitting $15.2 billion, up from $12.7 billion in 2019.</p><p>There is one other–rather large–point about regulatory credits. They aren’t going away. If anything, they will increase. Government support might morph from what Tesla sells today into new purchase tax credits or something else, but governments&nbsp;in China&nbsp;and&nbsp;the U.S.&nbsp;are looking to increase the number of EVs sold.</p><p>Refusing to deduct credit sales from operating income doesn’t make an investor a Tesla devotee. There are plenty of reasons people can choose to avoid the stock.Valuation&nbsp;being chief among them. Tesla is the world’s most valuable auto maker by a factor of roughly three even though it makes a fraction of the cars that&nbsp;Toyota Motor(TM), the second most valuable car company, does.</p><p>Valuation is a stale reason to dislike the stock. People have been complaining about valuation for a long time. Investors can also decide that competition is ramping higher or that full self-driving technology will take longer to develop than Tesla currently believes and suggests. Autonomous driving isn’t easy. Elon Musk calls it the company’s hardest challenge and its biggest potential value creator.</p><p>There is something in Tesla stock for full self-driving technology. How much is hard to say. Morgan Stanley analyst&nbsp;Adam Jonas&nbsp;values Tesla mobility and network services business opportunities at roughly $330 a share.</p><p>Those include software sales and robotaxis–both businesses are dependent on autonomous driving technology. His value is almost half of Tesla’s current stock price. Although Jonas’ Tesla target is $900 a share, making those business closer to one-third of the value he sees in the company.</p><p>Autonomous hiccups, valuation and competition should be enough reason to avoid the stock. Just stop saying the company doesn’t make money without regulatory credits.</p><p><img src=\"https://static.tigerbbs.com/e1c3a39d4d3c30a7fca792adc5b14fb7\" tg-width=\"1049\" tg-height=\"700\" referrerpolicy=\"no-referrer\"></p><p>Tesla shares are down about 2% year to date, trailing behind comparable gains of the&nbsp;S&amp;P 500&nbsp;and&nbsp;Dow Jones Industrial Average.Investors aren’t worried about the credit conundrum. They are waiting for quarterly operating profits to set new highs. When, and if, it does, they won’t care about the composition of the operating profit.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Stock Has Many Risks. EV Credits Isn’t One of Them.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Stock Has Many Risks. EV Credits Isn’t One of Them.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 15:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/tesla-haters-are-harping-on-emissions-credit-sales-investors-shouldnt-worry-51619652841><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla bears need to stop harping on regulatory credit sales. The oft-repeated refrain is that Tesla isn’t profitable without credit sales. There are plenty of reasons bears can avoid Tesla stock, but ...</p>\n\n<a href=\"https://www.barrons.com/articles/tesla-haters-are-harping-on-emissions-credit-sales-investors-shouldnt-worry-51619652841\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.barrons.com/articles/tesla-haters-are-harping-on-emissions-credit-sales-investors-shouldnt-worry-51619652841","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109392198","content_text":"Tesla bears need to stop harping on regulatory credit sales. The oft-repeated refrain is that Tesla isn’t profitable without credit sales. There are plenty of reasons bears can avoid Tesla stock, but credits Tesla earns, and then sells for cash to other auto makers, for producing more than its shares of zero emission vehicles isn’t one of them.Tesla sold more than $500 million in regulatory credits in the first quarter and generated just under $600 million in operating profit. Excluding the credits, Tesla only eked out a small operating profit.But saying Tesla isn’t profitable without regulatory credits is falling victim to the fallacy of the predetermined outcome. It’s like saying the New York Jets lost a football game because of a bad call in the first quarter. There are many reasons the Jets lose and a refereeing mistakes aren’t one of them.To drive the analogy further, any Jets game would be totally different if the ref didn’t mess up. A penalty not called, or called, changes each subsequent play in unknown ways. If Tesla didn’t have regulatory credits to sell, the company would have to raise prices or cut costs or do something else to make money. The company would adapt to the situation.Raising prices could be a way to go, but higher prices, of course, have their own impact, potentially reducing demand. Tesla still managed to grow sales even after the company lost its $7,500 U.S. federal tax credit. That isn’t available to Tesla buyers any longer because Tesla has sold too many EVs to qualify.Tesla lost that federal credit at the end of 2019. It was effectively a $7,500 price increase in the U.S. on Jan. 1, 2020. Tesla sales in the U.S. grew 20% this past year, hitting $15.2 billion, up from $12.7 billion in 2019.There is one other–rather large–point about regulatory credits. They aren’t going away. If anything, they will increase. Government support might morph from what Tesla sells today into new purchase tax credits or something else, but governments in China and the U.S. are looking to increase the number of EVs sold.Refusing to deduct credit sales from operating income doesn’t make an investor a Tesla devotee. There are plenty of reasons people can choose to avoid the stock.Valuation being chief among them. Tesla is the world’s most valuable auto maker by a factor of roughly three even though it makes a fraction of the cars that Toyota Motor(TM), the second most valuable car company, does.Valuation is a stale reason to dislike the stock. People have been complaining about valuation for a long time. Investors can also decide that competition is ramping higher or that full self-driving technology will take longer to develop than Tesla currently believes and suggests. Autonomous driving isn’t easy. Elon Musk calls it the company’s hardest challenge and its biggest potential value creator.There is something in Tesla stock for full self-driving technology. How much is hard to say. Morgan Stanley analyst Adam Jonas values Tesla mobility and network services business opportunities at roughly $330 a share.Those include software sales and robotaxis–both businesses are dependent on autonomous driving technology. His value is almost half of Tesla’s current stock price. Although Jonas’ Tesla target is $900 a share, making those business closer to one-third of the value he sees in the company.Autonomous hiccups, valuation and competition should be enough reason to avoid the stock. Just stop saying the company doesn’t make money without regulatory credits.Tesla shares are down about 2% year to date, trailing behind comparable gains of the S&P 500 and Dow Jones Industrial Average.Investors aren’t worried about the credit conundrum. They are waiting for quarterly operating profits to set new highs. When, and if, it does, they won’t care about the composition of the operating profit.","news_type":1},"isVote":1,"tweetType":1,"viewCount":30,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887993319,"gmtCreate":1631953067731,"gmtModify":1676530677642,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/887993319","repostId":"1197410423","repostType":4,"repost":{"id":"1197410423","pubTimestamp":1631932844,"share":"https://www.laohu8.com/m/news/1197410423?lang=&edition=full","pubTime":"2021-09-18 10:40","market":"us","language":"en","title":"HLBZ Stock: What to Know as Little-Known Helbiz Rockets Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=1197410423","media":"investorplace","summary":"One of the fastest-moving stocks today is Helbiz(NASDAQ:HLBZ). Indeed, today’s price action in HLBZ ","content":"<p>One of the fastest-moving stocks today is&nbsp;<b>Helbiz</b>(NASDAQ:<b><u>HLBZ</u></b>). Indeed, today’s price action in HLBZ stock has been incredible to see, with shares of this micro-mobility company skyrocketing more than 140% at the time of writing.</p>\n<p>This is yet another de-SPAC company that recently closed its merger on Aug. 13. Since then, shares went from the $10 IPO price level to the $6 per share level. However, today’s price action has driven shares of HLBZ stock to more than $25 per share, representing a 4-bagger from lows seen just a few weeks ago.</p>\n<p>Post-SPAC merger volatility has certainly been the norm of late. However, for Helbiz and its de-SPAC peers, most of this volatility has been to the downside. Let’s dive into what is driving HLBZ stock higher today.</p>\n<p>HLBZ Stock Surging on Media Rights Deal</p>\n<p>Most folks know of Helbiz as a global leader in the&nbsp;micro-mobility market. You know, scooters and other various forms of car-free transportation to get around big cities.</p>\n<p>However, Helbiz is also a company looking to make waves in the streaming and entertainment space. Via its subsidiary Helbiz Media, the company has&nbsp;announced&nbsp;today a key partnership that could spur a tremendous amount of growth from here.</p>\n<p>This partnership is between Helbiz Media and&nbsp;<b>FOX Networks Group</b>&nbsp;to broadcast the Italian Series B championship in the U.S. and Caribbean. Perhaps a smaller deal relative to the rest of the streaming space, this three-year contract could provide Helbiz with some nice momentum in a niche market for sports streaming.</p>\n<p>For now, it appears investors like the way Helbiz’s management team is positioning the company. Whether or not this valuation can be maintained remains to be seen. However, today’s impressive upward spike in HLBZ stock is certainly worth watching.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HLBZ Stock: What to Know as Little-Known Helbiz Rockets Higher</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHLBZ Stock: What to Know as Little-Known Helbiz Rockets Higher\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 10:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/hlbz-stock-what-to-know-as-little-known-helbiz-rockets-higher/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>One of the fastest-moving stocks today is Helbiz(NASDAQ:HLBZ). Indeed, today’s price action in HLBZ stock has been incredible to see, with shares of this micro-mobility company skyrocketing more than ...</p>\n\n<a href=\"https://investorplace.com/2021/09/hlbz-stock-what-to-know-as-little-known-helbiz-rockets-higher/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/09/hlbz-stock-what-to-know-as-little-known-helbiz-rockets-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197410423","content_text":"One of the fastest-moving stocks today is Helbiz(NASDAQ:HLBZ). Indeed, today’s price action in HLBZ stock has been incredible to see, with shares of this micro-mobility company skyrocketing more than 140% at the time of writing.\nThis is yet another de-SPAC company that recently closed its merger on Aug. 13. Since then, shares went from the $10 IPO price level to the $6 per share level. However, today’s price action has driven shares of HLBZ stock to more than $25 per share, representing a 4-bagger from lows seen just a few weeks ago.\nPost-SPAC merger volatility has certainly been the norm of late. However, for Helbiz and its de-SPAC peers, most of this volatility has been to the downside. Let’s dive into what is driving HLBZ stock higher today.\nHLBZ Stock Surging on Media Rights Deal\nMost folks know of Helbiz as a global leader in the micro-mobility market. You know, scooters and other various forms of car-free transportation to get around big cities.\nHowever, Helbiz is also a company looking to make waves in the streaming and entertainment space. Via its subsidiary Helbiz Media, the company has announced today a key partnership that could spur a tremendous amount of growth from here.\nThis partnership is between Helbiz Media and FOX Networks Group to broadcast the Italian Series B championship in the U.S. and Caribbean. Perhaps a smaller deal relative to the rest of the streaming space, this three-year contract could provide Helbiz with some nice momentum in a niche market for sports streaming.\nFor now, it appears investors like the way Helbiz’s management team is positioning the company. Whether or not this valuation can be maintained remains to be seen. However, today’s impressive upward spike in HLBZ stock is certainly worth watching.","news_type":1},"isVote":1,"tweetType":1,"viewCount":53,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888733410,"gmtCreate":1631527413330,"gmtModify":1676530566012,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/888733410","repostId":"1133730816","repostType":4,"isVote":1,"tweetType":1,"viewCount":53,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814229897,"gmtCreate":1630827889019,"gmtModify":1676530402527,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/814229897","repostId":"1157895022","repostType":4,"repost":{"id":"1157895022","pubTimestamp":1630810619,"share":"https://www.laohu8.com/m/news/1157895022?lang=&edition=full","pubTime":"2021-09-05 10:56","market":"us","language":"en","title":"Beat the market with this quant system that’s very bullish on stocks at record highs","url":"https://stock-news.laohu8.com/highlight/detail?id=1157895022","media":"MarketWatch","summary":"Vance Howard’s HCM Tactical Growth Fund moves you in and out of the stock market when prudent to do ","content":"<blockquote>\n <b>Vance Howard’s HCM Tactical Growth Fund moves you in and out of the stock market when prudent to do so. So far his team of computer scientists’ strategy has paid off.</b>\n</blockquote>\n<p>Imagine you had a money-making machine to harvest gains in the stock market while you sat back to enjoy life.</p>\n<p>That’s everyone’s dream, right? Investor Vance Howard thinks he’s found it.</p>\n<p>Howard and his small army of computer programmers atHoward Capital Managementin Roswell, Ga., have a quantitative system that posts great returns.</p>\n<p>His HCM Tactical Growth Fund&nbsp;HCMGX,+0.35%beats its Russell 1000&nbsp;benchmark index and large-blend fund category by 8.5-10.4 percentage points annualized over the past five years, according to Morningstar. That is no small feat, and not only because it has to overcome a 2.22% fee. Beating the market is simply not easy. His HCM Dividend Sector PlusHCMQX,-0.05%) and HCM Income PlusHCMLX,+0.30%funds post similar outperformance.</p>\n<p>There are drawbacks, which I detail below. (Among them: Potentially long stretches of underperformance and regular tax bills.) But first, what can we learn from this winner?</p>\n<p>So-called quants never share all the details of their proprietary systems, but Howard shares a lot, as you’ll see. And this Texas rancher has a lot of good advice based on “horse sense” — not surprising, given his infectious passion for the markets, and his three decades of experience as a pro.</p>\n<p>Here are five lessons, 12 exchange traded funds (ETFs) and four stocks to consider, from a recent interview with him.</p>\n<p><b>Lesson #1: Don’t be emotional</b></p>\n<p>It’s no surprise so many people do poorly in the market. Evolution has programmed us to fail. For survival, we’ve learned to run from things that frightens us. And crave more of things that are pleasurable — like sweets or fats to store calories ahead of what might be a long stretch without food. But in the market, acting on the emotions of fear and greed invariably make us do the wrong thing at the wrong time. Sell at the bottom, buy at the top.</p>\n<p>Likewise, we’re programmed to believe being with the crowd brings safety. If you’re a zebra on the Savanna, you are more likely to get picked off by a predator if you go it alone. The problem here is being part of a crowd — and crowd psychology — dumb us down to a purely emotional level. This is why people in crowds do terrible things they would never do on their own. It doesn’t matter how smart you are. When you join a crowd, you lose a lot of IQ points. Base emotions take over.</p>\n<p>To do well in the market, you have to counteract these tendencies. “One of the biggest mistakes individual investors and money managers make is getting emotional,” says Howard. “Let your emotions go.”</p>\n<p><b>Lesson #2: Have a system and stick to it</b></p>\n<p>To exorcise emotion, have a system. “And don’t second guess it,” says Howard. “This keeps you from letting the pandemic or Afghanistan scare you out of the market.” He calls his system the HCM-BuyLine. It is basically a momentum and trend-following system — which often works well in the markets.</p>\n<p>The HCM-BuyLine basically works like this. First, rather than use the S&amp;P 500SPX,-0.03%or the Dow Jones Industrial AverageDJIA,-0.21%,Howard blends several stock indices to create his own index. Then he uses a moving average that tells him whether the market is in an uptrend or downtrend.</p>\n<p>When the moving average drops 3.5%, he sells 35%. If it drops 6.5%, he sells another 35%. He rarely goes to 100% cash.</p>\n<p>“If the BuyLine is positive, we will stay long no matter what,” he says. “We take all the emotion out of the equation by letting the math decide.”</p>\n<p>Right now, it’s bullish. (More on this below.)</p>\n<p>Your system also has to tell you when to get back in.</p>\n<p>“That’s where most people screw up,” he says. “They get out of the market, and they don’t know when to get back in.” The HCM-BuyLine gives a buy signal when his custom index trades above its moving average for six consecutive sessions, and then goes on to trade above the high hit during those six days.</p>\n<p>You don’t need a system that calls exact market tops or bottoms. Instead, the BuyLine keeps Howard out of down markets 85% of the time, and in for 85% of the good times.</p>\n<p>“If we can do that consistently, we have superior returns and a less stressful life,” he says. “Being all in during a bad tape is no fun.”</p>\n<p>His system is slow to get him out of the market, but quick to get him back in. Not even a 10% correction will necessarily move him out. He’s often buying those pullbacks. Getting back in fast makes sense, because recoveries off bottoms tend to happen fast.</p>\n<p>“The HCM-BuyLine takes all the emotion out of the process,” says Howard.</p>\n<p><b>Lesson #3: Don’t fight the tape</b></p>\n<p>This concept is one of the core pieces of wisdom from Marty Zweig’s classic book, “Winning on Wall Street.”</p>\n<p>“You have to stay on the right side of market,” agrees Howard. “If you try to trade long in a bad market, it is painful.”</p>\n<p>In other words, don’t try to be a hero.</p>\n<p>“Sometimes, not losing money is where you want to be,” he says.</p>\n<p>Likewise, don’t turn cautious just because the market hits new highs — like now. You should love new highs, because it is a sign of market strength that may likely endure.</p>\n<p><b>Lesson #4: Keep it simple</b></p>\n<p>As you’ll see below, Howard doesn’t use esoteric instruments such as derivatives, swaps or index options. He doesn’t even trade foreign stocks or currencies. This is refreshing for individual investors, because we have a harder time accessing those tools.</p>\n<p>“You don’t have to trade crazy stuff,” he says. “You can trade plain-vanilla ETFs and beat everybody out there.”</p>\n<p><b>Lesson #5: How to trade the current market</b></p>\n<p>First, be long.</p>\n<p>“The HCM-BuyLine is very positive. We are 100% in,” says Howard. “The market is broadening out. It is getting pretty exciting. We do not see it turn around any time soon. We are buying pullbacks.”</p>\n<p>One bullish signal is all the cash on the sidelines. “If there is any relief in Covid, we may see a big rally. We may end up with a great fall [season].”</p>\n<p>Howard uses momentum indicators to select stocks and ETFs, too. For sectors he favors the following.</p>\n<p>He likes health care, tradable through the iShares US HealthcareIYH,-0.04%and ProShares Ultra Health CareRXL,+0.12%ETFs. He’s turning more bullish on biotech, which he plays via the iShares Biotechnology ETFIBB,-0.11%.</p>\n<p>He likes consumer discretionary tradable through the iShares US Consumer ServicesIYC,-0.30%,and airlines via US Global JetsJETS,-1.17%.He also likes tech exposure via the Invesco QQQ TrustQQQ,+0.31%,iShares US TechnologyIYW,+0.50%and&nbsp;iShares SemiconductorSOXX,+0.75%.</p>\n<p>He likes small-caps via the Vanguard Small-Cap Growth Index FundVBK,+0.07%.And convertible bonds via SPDR Bloomberg Barclays Convertible SecuritiesCWB,+0.64%and iShares Convertible BondICVT,+0.37%.</p>\n<p>As for individual names, he singles out MicrosoftMSFT,-0.00%and AppleAAPL,+0.42%in tech, as well as Amazon.comAMZN,+0.43%and TeslaTSLA,+0.16%.</p>\n<p>Also consider Howard’s two ETFs: The HCM Defender 100 IndexQQH,+0.62%and HCM Defender 500 IndexLGH,+1.32%.</p>\n<p>He prefers to add to holdings on 1%-3% dips.</p>\n<p><b>A few drawbacks</b></p>\n<p>His HCM Tactical Growth fund has a history of posting two-year stretches of underperformance of 1.5% to 8.8%, since it was launched in 2015. The fund then came roaring back to net the very positive five-year outperformance cited above. Investing in his system can require patience.</p>\n<p>Every manager, including Warren Buffett, can have a stretch of underperformance, says Howard.</p>\n<p>“We are in the odds game,” he says. “Even in the odds game, you can have a bad hand or two thrown at you.”</p>\n<p>Another challenge is the high turnover, which is 140% a year for Tactical Growth. This means Uncle Sam takes a big cut in the good years. So if you buy Howard’s funds, you may want to do so in a tax-protected account.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beat the market with this quant system that’s very bullish on stocks at record highs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeat the market with this quant system that’s very bullish on stocks at record highs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-05 10:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/beat-the-market-with-this-quant-system-thats-very-bullish-on-stocks-at-record-highs-11630761531?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vance Howard’s HCM Tactical Growth Fund moves you in and out of the stock market when prudent to do so. So far his team of computer scientists’ strategy has paid off.\n\nImagine you had a money-making ...</p>\n\n<a href=\"https://www.marketwatch.com/story/beat-the-market-with-this-quant-system-thats-very-bullish-on-stocks-at-record-highs-11630761531?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".DJI":"道琼斯"},"source_url":"https://www.marketwatch.com/story/beat-the-market-with-this-quant-system-thats-very-bullish-on-stocks-at-record-highs-11630761531?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157895022","content_text":"Vance Howard’s HCM Tactical Growth Fund moves you in and out of the stock market when prudent to do so. So far his team of computer scientists’ strategy has paid off.\n\nImagine you had a money-making machine to harvest gains in the stock market while you sat back to enjoy life.\nThat’s everyone’s dream, right? Investor Vance Howard thinks he’s found it.\nHoward and his small army of computer programmers atHoward Capital Managementin Roswell, Ga., have a quantitative system that posts great returns.\nHis HCM Tactical Growth Fund HCMGX,+0.35%beats its Russell 1000 benchmark index and large-blend fund category by 8.5-10.4 percentage points annualized over the past five years, according to Morningstar. That is no small feat, and not only because it has to overcome a 2.22% fee. Beating the market is simply not easy. His HCM Dividend Sector PlusHCMQX,-0.05%) and HCM Income PlusHCMLX,+0.30%funds post similar outperformance.\nThere are drawbacks, which I detail below. (Among them: Potentially long stretches of underperformance and regular tax bills.) But first, what can we learn from this winner?\nSo-called quants never share all the details of their proprietary systems, but Howard shares a lot, as you’ll see. And this Texas rancher has a lot of good advice based on “horse sense” — not surprising, given his infectious passion for the markets, and his three decades of experience as a pro.\nHere are five lessons, 12 exchange traded funds (ETFs) and four stocks to consider, from a recent interview with him.\nLesson #1: Don’t be emotional\nIt’s no surprise so many people do poorly in the market. Evolution has programmed us to fail. For survival, we’ve learned to run from things that frightens us. And crave more of things that are pleasurable — like sweets or fats to store calories ahead of what might be a long stretch without food. But in the market, acting on the emotions of fear and greed invariably make us do the wrong thing at the wrong time. Sell at the bottom, buy at the top.\nLikewise, we’re programmed to believe being with the crowd brings safety. If you’re a zebra on the Savanna, you are more likely to get picked off by a predator if you go it alone. The problem here is being part of a crowd — and crowd psychology — dumb us down to a purely emotional level. This is why people in crowds do terrible things they would never do on their own. It doesn’t matter how smart you are. When you join a crowd, you lose a lot of IQ points. Base emotions take over.\nTo do well in the market, you have to counteract these tendencies. “One of the biggest mistakes individual investors and money managers make is getting emotional,” says Howard. “Let your emotions go.”\nLesson #2: Have a system and stick to it\nTo exorcise emotion, have a system. “And don’t second guess it,” says Howard. “This keeps you from letting the pandemic or Afghanistan scare you out of the market.” He calls his system the HCM-BuyLine. It is basically a momentum and trend-following system — which often works well in the markets.\nThe HCM-BuyLine basically works like this. First, rather than use the S&P 500SPX,-0.03%or the Dow Jones Industrial AverageDJIA,-0.21%,Howard blends several stock indices to create his own index. Then he uses a moving average that tells him whether the market is in an uptrend or downtrend.\nWhen the moving average drops 3.5%, he sells 35%. If it drops 6.5%, he sells another 35%. He rarely goes to 100% cash.\n“If the BuyLine is positive, we will stay long no matter what,” he says. “We take all the emotion out of the equation by letting the math decide.”\nRight now, it’s bullish. (More on this below.)\nYour system also has to tell you when to get back in.\n“That’s where most people screw up,” he says. “They get out of the market, and they don’t know when to get back in.” The HCM-BuyLine gives a buy signal when his custom index trades above its moving average for six consecutive sessions, and then goes on to trade above the high hit during those six days.\nYou don’t need a system that calls exact market tops or bottoms. Instead, the BuyLine keeps Howard out of down markets 85% of the time, and in for 85% of the good times.\n“If we can do that consistently, we have superior returns and a less stressful life,” he says. “Being all in during a bad tape is no fun.”\nHis system is slow to get him out of the market, but quick to get him back in. Not even a 10% correction will necessarily move him out. He’s often buying those pullbacks. Getting back in fast makes sense, because recoveries off bottoms tend to happen fast.\n“The HCM-BuyLine takes all the emotion out of the process,” says Howard.\nLesson #3: Don’t fight the tape\nThis concept is one of the core pieces of wisdom from Marty Zweig’s classic book, “Winning on Wall Street.”\n“You have to stay on the right side of market,” agrees Howard. “If you try to trade long in a bad market, it is painful.”\nIn other words, don’t try to be a hero.\n“Sometimes, not losing money is where you want to be,” he says.\nLikewise, don’t turn cautious just because the market hits new highs — like now. You should love new highs, because it is a sign of market strength that may likely endure.\nLesson #4: Keep it simple\nAs you’ll see below, Howard doesn’t use esoteric instruments such as derivatives, swaps or index options. He doesn’t even trade foreign stocks or currencies. This is refreshing for individual investors, because we have a harder time accessing those tools.\n“You don’t have to trade crazy stuff,” he says. “You can trade plain-vanilla ETFs and beat everybody out there.”\nLesson #5: How to trade the current market\nFirst, be long.\n“The HCM-BuyLine is very positive. We are 100% in,” says Howard. “The market is broadening out. It is getting pretty exciting. We do not see it turn around any time soon. We are buying pullbacks.”\nOne bullish signal is all the cash on the sidelines. “If there is any relief in Covid, we may see a big rally. We may end up with a great fall [season].”\nHoward uses momentum indicators to select stocks and ETFs, too. For sectors he favors the following.\nHe likes health care, tradable through the iShares US HealthcareIYH,-0.04%and ProShares Ultra Health CareRXL,+0.12%ETFs. He’s turning more bullish on biotech, which he plays via the iShares Biotechnology ETFIBB,-0.11%.\nHe likes consumer discretionary tradable through the iShares US Consumer ServicesIYC,-0.30%,and airlines via US Global JetsJETS,-1.17%.He also likes tech exposure via the Invesco QQQ TrustQQQ,+0.31%,iShares US TechnologyIYW,+0.50%and iShares SemiconductorSOXX,+0.75%.\nHe likes small-caps via the Vanguard Small-Cap Growth Index FundVBK,+0.07%.And convertible bonds via SPDR Bloomberg Barclays Convertible SecuritiesCWB,+0.64%and iShares Convertible BondICVT,+0.37%.\nAs for individual names, he singles out MicrosoftMSFT,-0.00%and AppleAAPL,+0.42%in tech, as well as Amazon.comAMZN,+0.43%and TeslaTSLA,+0.16%.\nAlso consider Howard’s two ETFs: The HCM Defender 100 IndexQQH,+0.62%and HCM Defender 500 IndexLGH,+1.32%.\nHe prefers to add to holdings on 1%-3% dips.\nA few drawbacks\nHis HCM Tactical Growth fund has a history of posting two-year stretches of underperformance of 1.5% to 8.8%, since it was launched in 2015. The fund then came roaring back to net the very positive five-year outperformance cited above. Investing in his system can require patience.\nEvery manager, including Warren Buffett, can have a stretch of underperformance, says Howard.\n“We are in the odds game,” he says. “Even in the odds game, you can have a bad hand or two thrown at you.”\nAnother challenge is the high turnover, which is 140% a year for Tactical Growth. This means Uncle Sam takes a big cut in the good years. So if you buy Howard’s funds, you may want to do so in a tax-protected account.","news_type":1},"isVote":1,"tweetType":1,"viewCount":34,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":830776951,"gmtCreate":1629103281173,"gmtModify":1676529930791,"author":{"id":"3565687171198207","authorId":"3565687171198207","name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/830776951","repostId":"1122515246","repostType":4,"repost":{"id":"1122515246","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629102696,"share":"https://www.laohu8.com/m/news/1122515246?lang=&edition=full","pubTime":"2021-08-16 16:31","market":"other","language":"en","title":"Wish, Palantir, AMC, Clover Heealth, GameStop And More — Stocks On WallStreetBets Radar Heading Into New Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1122515246","media":"Benzinga","summary":"Heading into a new trading week, ContextLogic Inc., Palantir Technologies Inc., AMC Entertainment an","content":"<p>Heading into a new trading week,&nbsp;<b><a href=\"https://laohu8.com/S/WISH\">ContextLogic Inc.</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/PLTR\">Palantir Technologies Inc.</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/AMC\">AMC Entertainment</a></b> and&nbsp;<b><a href=\"https://laohu8.com/S/CLOV\">Clover Health Corp</a></b> are&nbsp;among&nbsp;the stocksseeing the highest intereston Reddit’s r/WallStreetBets forum.</p>\n<p><b>What Happened</b>: Exchange-traded fund&nbsp;<b>S&amp;P SPDR 500 ETF Trust</b></p>\n<p>SPY&nbsp;is seeing the highest interest on the forum with 132 mentions, followed by e-commerce company ContextLogic with 51 mentions, data from Quiver Quantitative showed.</p>\n<p>Software company Palantir Technologies and movie theatre chain AMC Entertainment are in the third and fourth positions, having attracted 31 and 29 mentions, respectively.</p>\n<p>Apart from Medicare Advantage provider Clover Health, the other stocks that are trending on the forum include videogame retailer&nbsp;<b><a href=\"https://laohu8.com/S/GME\">GameStop</a></b>, aerospace and defense company<b>&nbsp;<a href=\"https://laohu8.com/S/LMT\">Lockheed Martin</a></b>, transportation and logistics company&nbsp;<b><a href=\"https://laohu8.com/S/R\">Ryder</a></b>, lithium-ion battery maker&nbsp;<b><a href=\"https://laohu8.com/S/MVST\">Microvast Holdings, Inc.</a> </b>and biotechnology company&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b><b>.</b></p>\n<p><b>Why It Matters</b>: ContextLogic’s shares fell almost 20% on Friday after the company received&nbsp;downgrades&nbsp;from Cowen and JPMorgan analysts following the announcement of worse-than-expected second-quarter financial results last Thursday.&nbsp;<b>Bank of America</b>&nbsp;analyst&nbsp;<b>Michael McGovern</b>&nbsp;also&nbsp;downgraded&nbsp;the company’s shares from Neutral to Underperform.</p>\n<p>AMC Entertainment is seeing high interest from retail investors. Aposton the WSB forum noted that the lower volatility and volume in AMC Entertainment’s shares is good news for the bulls as it indicates that the “bears have lost some steam.”</p>\n<p>Lockheed Martin is seeing high interest on the WSB forum after it wasreportedthat the President of Afghanistan<b>Ashraf Ghani</b>has fled his country as Taliban fighters entered the capital city of Kabul. The stock is seeing as benefiting from the turmoil in Afghanistan.</p>\n<p><b>Price Action</b>: <a href=\"https://laohu8.com/S/SPY.AU\">SPDR® S&amp;P 500® ETF Trust</a> shares closed almost 0.2% higher in Friday’s trading at $445.92, while ContextLogic shares closed almost 19.8% lower at $7.55.</p>\n<p>Palantir Technologies shares closed less than 0.1% higher in Friday’s trading session at $24.90.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wish, Palantir, AMC, Clover Heealth, GameStop And More — Stocks On WallStreetBets Radar Heading Into New Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWish, Palantir, AMC, Clover Heealth, GameStop And More — Stocks On WallStreetBets Radar Heading Into New Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-16 16:31</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Heading into a new trading week,&nbsp;<b><a href=\"https://laohu8.com/S/WISH\">ContextLogic Inc.</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/PLTR\">Palantir Technologies Inc.</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/AMC\">AMC Entertainment</a></b> and&nbsp;<b><a href=\"https://laohu8.com/S/CLOV\">Clover Health Corp</a></b> are&nbsp;among&nbsp;the stocksseeing the highest intereston Reddit’s r/WallStreetBets forum.</p>\n<p><b>What Happened</b>: Exchange-traded fund&nbsp;<b>S&amp;P SPDR 500 ETF Trust</b></p>\n<p>SPY&nbsp;is seeing the highest interest on the forum with 132 mentions, followed by e-commerce company ContextLogic with 51 mentions, data from Quiver Quantitative showed.</p>\n<p>Software company Palantir Technologies and movie theatre chain AMC Entertainment are in the third and fourth positions, having attracted 31 and 29 mentions, respectively.</p>\n<p>Apart from Medicare Advantage provider Clover Health, the other stocks that are trending on the forum include videogame retailer&nbsp;<b><a href=\"https://laohu8.com/S/GME\">GameStop</a></b>, aerospace and defense company<b>&nbsp;<a href=\"https://laohu8.com/S/LMT\">Lockheed Martin</a></b>, transportation and logistics company&nbsp;<b><a href=\"https://laohu8.com/S/R\">Ryder</a></b>, lithium-ion battery maker&nbsp;<b><a href=\"https://laohu8.com/S/MVST\">Microvast Holdings, Inc.</a> </b>and biotechnology company&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b><b>.</b></p>\n<p><b>Why It Matters</b>: ContextLogic’s shares fell almost 20% on Friday after the company received&nbsp;downgrades&nbsp;from Cowen and JPMorgan analysts following the announcement of worse-than-expected second-quarter financial results last Thursday.&nbsp;<b>Bank of America</b>&nbsp;analyst&nbsp;<b>Michael McGovern</b>&nbsp;also&nbsp;downgraded&nbsp;the company’s shares from Neutral to Underperform.</p>\n<p>AMC Entertainment is seeing high interest from retail investors. Aposton the WSB forum noted that the lower volatility and volume in AMC Entertainment’s shares is good news for the bulls as it indicates that the “bears have lost some steam.”</p>\n<p>Lockheed Martin is seeing high interest on the WSB forum after it wasreportedthat the President of Afghanistan<b>Ashraf Ghani</b>has fled his country as Taliban fighters entered the capital city of Kabul. The stock is seeing as benefiting from the turmoil in Afghanistan.</p>\n<p><b>Price Action</b>: <a href=\"https://laohu8.com/S/SPY.AU\">SPDR® S&amp;P 500® ETF Trust</a> shares closed almost 0.2% higher in Friday’s trading at $445.92, while ContextLogic shares closed almost 19.8% lower at $7.55.</p>\n<p>Palantir Technologies shares closed less than 0.1% higher in Friday’s trading session at $24.90.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc.","CLOV":"Clover Health Corp","SPY.AU":"SPDR® S&P 500® ETF Trust"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122515246","content_text":"Heading into a new trading week, ContextLogic Inc., Palantir Technologies Inc., AMC Entertainment and Clover Health Corp are among the stocksseeing the highest intereston Reddit’s r/WallStreetBets forum.\nWhat Happened: Exchange-traded fund S&P SPDR 500 ETF Trust\nSPY is seeing the highest interest on the forum with 132 mentions, followed by e-commerce company ContextLogic with 51 mentions, data from Quiver Quantitative showed.\nSoftware company Palantir Technologies and movie theatre chain AMC Entertainment are in the third and fourth positions, having attracted 31 and 29 mentions, respectively.\nApart from Medicare Advantage provider Clover Health, the other stocks that are trending on the forum include videogame retailer GameStop, aerospace and defense company Lockheed Martin, transportation and logistics company Ryder, lithium-ion battery maker Microvast Holdings, Inc. and biotechnology company Pfizer.\nWhy It Matters: ContextLogic’s shares fell almost 20% on Friday after the company received downgrades from Cowen and JPMorgan analysts following the announcement of worse-than-expected second-quarter financial results last Thursday. Bank of America analyst Michael McGovern also downgraded the company’s shares from Neutral to Underperform.\nAMC Entertainment is seeing high interest from retail investors. Aposton the WSB forum noted that the lower volatility and volume in AMC Entertainment’s shares is good news for the bulls as it indicates that the “bears have lost some steam.”\nLockheed Martin is seeing high interest on the WSB forum after it wasreportedthat the President of AfghanistanAshraf Ghanihas fled his country as Taliban fighters entered the capital city of Kabul. The stock is seeing as benefiting from the turmoil in Afghanistan.\nPrice Action: SPDR® S&P 500® ETF Trust shares closed almost 0.2% higher in Friday’s trading at $445.92, while ContextLogic shares closed almost 19.8% lower at $7.55.\nPalantir Technologies shares closed less than 0.1% higher in Friday’s trading session at $24.90.","news_type":1},"isVote":1,"tweetType":1,"viewCount":10,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}